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ABSTRACT 
UDP-glucuronosyltransferase (UGT) enzymes are responsible for the metabolism of many 
xenobiotics, as well as several endogenous compounds like bilirubin and certain steroids. 
This thesis involves three major themes: UGT1A1 and Crigler-Najjar syndrome; 
expression and characterisation of a novel UGT, UGT2A2; and the glucuronidation of 
various endogenous and synthetic steroids.  
 
Fourteen different UGT1A1 mutations were identified in 19 CN patients, four of which 
were novel. The mutant proteins were expressed in baculovirus infected Sf9 insect cells 
and their activity towards bilirubin and other substrates was determined. Residual 
glucuronidation activity and the severity of hyperbilirubinemia were found to correlate 
well  in  most  cases.  In  addition,  a  major  advancement  to  aid  the  development  of  gene  
therapy for CN was achieved by in discovering that ezetimibe glucuronidation correlates 
with reduction of serum bilirubin in gene therapy treated Gunn rats. This compound might 
be useful in examining the efficacy of gene therapy in humans in the future. 
 
When the novel UGT2A2 was cloned, expressed, and studied alongside UGTs 2A1 and 
2A3, results indicated that UGT2A2 is a functional enzyme with broad substrate 
specificity. The previously suggested exon sharing between UGT2A1 and UGT2A2 was 
also confirmed, and UGT2A2 was found to be expressed mainly in nasal mucosa, similar 
to UGT2A1. In addition, UGT2A1 and UGT2A2 were found to differ largely in their 
regioselectivity towards estrogens, and this encouraged us to further investigate the 
glucuronidation of steroids and the differences in how they are glucuronidated by the 
different human UGT enzymes. 
 
The glucuronidation of estriol, 16-epiestriol, 17-epiestriol, 13-epiestradiol, ent-estradiol, 
ent-androsterone, and ent-etiocholanolone by different UGT enzymes was studied and 
analytical methods for analysing these compounds were developed. UGTs 1A10 and 2B7 
were found to be the most active UGTs in the glucuronidation of almost every steroid 
studied. Several patterns in the regio- and stereoselectivity of steroid glucuronidation were 
observed for the first time. The effects of phenylalanines 93 and 90 on human UGT1A10 
on glucuronidation were also studied, exploiting site directed mutagenesis. The results 
revealed that F93 is involved in the interactions of the enzyme with estrogens, but the 
interactions with smaller molecules were found to be more complex and less drastic. A 
homology model of UGT1A10 was created based on the results. 
 
Knowledge of glucuronidation of endogenous compounds is important, since it may be 
directly or indirectly linked to clinical conditions and also because certain drugs that 
inhibit UGTs may inhibit the metabolic pathways of endogenous substrates that are 
metabolised by UGTs. Understanding the glucuronidation of steroids could be used to 
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make better predictions on the role of glucuronidation in the metabolism of newly 
designed drugs that resemble steroids. Detailed information on steroid glucuronidation 
may also be used in determining UGT structure via function and the results obtained 
during this PhD work may be used in the development of more detailed homology models 
of other UGT enzymes. 
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ABBREVIATIONS 
AAV Adeno-associated virus 
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CN-II Crigler-Najjar syndrome type II 
COMT Catechol-O-methyltransferase 
CYP Cytochrome P450 
DMSO Dimethyl sulfoxide 
E2 Estradiol 
E3 Estriol 
EED Ethinyl estradiol 
Ent Enantiomeric 
FDA US Food and Drug Administration  
GC Genome copy 
GS Gilbert syndrome 
HIM Human intestinal microsomes 
HLM Human liver microsomes 
HPLC High performance liquid chromatography 
ITR Inverted terminal repeat 
MeOH Methanol 
MS Mass spectrometry 
PCR Polymerase chain reaction 
pDNA Plasmid DNA 
qRT-PCR Quantitative real-time polymerase chain reaction 
RT-PCR Reverse transcription polymerase chain reaction  
scAAV Self-complementary adeno-associated virus 
SN2 Bimolecular nucleophilic substitution 
SULT Sulfotransferase 
UDP Uridine 5’-diphosphate 
UDPGA Uridine 5’-diphospho glucuronic acid 
UGT UDP-glucuronosyltransferase 
UGT Gene encoding UDP-glucuronosyltransferase 
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1. INTRODUCTION 
Metabolism, or biotransformation, is the most important elimination pathway for drugs 
and most of the drug metabolism takes place in the liver. Drug metabolism is usually 
divided into two phases: phase I includes functionalization reactions and phase II 
conjugation reactions (Fig. 1) (Gonzales et al., 2011; Wienkers and Heath, 2005; Evans 
and Relling, 1999). Metabolic reactions produce metabolites that can be active, even toxic, 
or inactive. Therefore the FDA encourages characterising metabolites at an early stage of 
drug discovery (www.fda.gov). Approximately 10% of the top 200 prescribed drugs that 
were recorded in the United States in 2002 are metabolised, at least partly, by uridine 5’-
diphospho glucuronosyltransferases (UDP-glucuronosyltransferases, UGTs). UGTs and 
cytochrome P450 enzymes (CYPs) are together responsible for the metabolism of most 
hepatically cleared drugs (Williams et al., 2004, www.rxlist.com). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Routes of drug elimination. A-D represent different elimination routes without metabolism (A) or Figure 1.
 through one or two metabolising phases (B-D). CYP: Cytochrome P450 enzymes; FMO: Flavin-
 containing monooxygenase; EH: Epoxide hydrolase; UGT: UDP-glucuronosyltransferase; SULT: 
 Sulfotransferase; GST: Glutathione S-transferase. 
While UGTs are important for the metabolism of drugs and other compounds that are 
foreign to humans, i.e. xenobiotics, they also have numerous endogenous substrates 
including bilirubin, bile acids and certain hormones, like steroids and thyroid hormones. 
There are many reasons why it is important to understand the glucuronidation of 
endogenous substrates. Firstly, endogenous glucuronidation may be linked directly to 
clinical conditions, like familial hyperbilirubinemias (see section 2.2 and publications II 
and V) and this knowledge may be utilized in genetic counseling of the patients and in 
Phase II 
CYPs 
FMOs 
EHs 
Etc. 
UGTs 
SULTs 
GSTs 
Etc. 
Phase I  
   
A
Excretion 
B C D
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developing new treatments. In addition, certain drugs inhibit UGTs and, therefore, may 
also inhibit the metabolic pathways of endogenous substrates that are primarily 
metabolised by UGTs. This is the case, for example, with atazanavir and increased risk of 
hyperbilirubinemia (Bentue-Ferrer et al., 2009), also making endogenous glucuronidation 
important for drug development. 
 
In cases other than bilirubin, like with steroid glucuronidation, the correlation between 
clinical conditions and glucuronidation is less direct and more research is needed to make 
relevant predictions, for example on the interplay between steroid glucuronidation and 
development of cancer (see section 2.3.). Understanding steroid glucuronidation may also 
help us in the future to make better predictions on the role of glucuronidation in the 
metabolism of synthetic estrogens that may be designed for cancer research and therapy 
(VI). 
 
While characterizing a novel UGT, UGT2A2 (I), numerous differences were encountered 
in regioselectivity of estrogen glucuronidation by UGTs, that were otherwise closely 
homologous. As relatively large and rigid molecules, steroids may serve as good 
candidates in determining UGTs structure via function and this approach has been 
exploited on several occasions (III, IV, VI) using both natural and synthetic steroids. 
 
In the following review of the literature, first, UGTs will be briefly discussed followed by 
a more detailed description of the selected endogenous UGT substrates. Bilirubin and 
familial hyperbilirubinemias will be discussed, as well as the emerging gene therapy 
treatments for Crigler-Najjar syndrome. This review will then cover the glucuronidation of 
steroids and the current knowledge on the correlation between steroid glucuronidation and 
medical conditions; followed, finally, by the use of steroids in predicting UGT structure. 
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2. REVIEW OF THE LITERATURE 
2.1 UDP-GLUCURONOSYLTRANSFERASES IN BRIEF 
 
Uridine 5'-diphospho-glucuronosyltransferases (UGTs, EC 2.4.1.17) are approximately 56 
kDa sized integral membrane proteins of the endoplasmic reticulum (ER). The human 
UGT1 and UGT2 subfamilies contain 19 different enzymes which share close sequence 
similarities,  especially  among  enzymes  of  the  same  subfamily  (Mackenzie  et  al.,  2005).  
UGT1As are encoded by a single large gene, UGT1. Each UGT1A protein is the product 
of a unique first exon, that encodes the N-terminal half of the protein, and four exons, 2-5, 
that  encode  the  C-terminal  half  of  the  protein  and  are  shared  among  all  UGT1As.  
UGT2A1 and UGT2A2 are also encoded by unique first exons and five shared exons, 
exons 2-6. UGT2A3 and UGT2Bs are comprised of six exons, 1-6, that are not shared and 
are unique for each UGT, even if they are highly homologous, particularly exons 2-6 that 
encode the C-terminal half of each enzyme (Mackenzie et al., 2005). Additionally, an 
alternative splicing at the exon 5 of the UGT1 locus leads to nine shorter UGT1A proteins. 
These alternative UGT isoforms lack enzymatic activity, but they may have a regulatory 
role in UGT function (Girard et al., 2007; Bellemare et al., 2010; Levesque et al., 2007).  
 
UGTs are expressed in various different tissues (Table 1). Liver carries the most abundant 
expression, but significant extrahepatic UGT expression is also evident, particularly in the 
kidney and gastrointestinal tract. Moreover, some UGTs, like UGT1A10, are exclusively 
or nearly exclusively extrahepatic. It is also noteworthy that many UGTs are expressed in 
steroid target tissues, like the testes and prostate. This will be discussed further in section 
2.3.1. 
 
While individual UGT enzymes are not discussed in detail in this section, UGT2As 
deserve some additional remarks since they are the subject of publication I. In 2008, when 
this PhD project was started, UGTs from subfamilies 1A and 2B had already been studied 
extensively and their expression patterns were well characterised. Much less was known 
about the three members of subfamily 2A: UGT2A1, UGT2A2, and UGT2A3. One major 
work on UGT2A1 had been published earlier showing, among other things, that this 
enzyme is mainly expressed in the nasal epithelium and that it has considerably broad 
substrate specificity (Jedlitschky et al., 1999). UGT2A1 was suggested to be involved in 
odorant signal termination (Jedlitschky et al., 1999; Lazard et al., 1991) and 
glucuronidated odorant molecules have indeed been shown to be unable to induce 
olfactory response (Thiebaud et al., 2013). In 2008, a comprehensive work about UGT2A3 
was published (Court et al., 2008). The expression pattern and activity of UGT2A3 were 
found to be very different compared to UGT2A1. The expression tissues included liver, 
adipose tissue, and parts of the GI tract and only few bile acids were found to be substrates 
for this enzyme. Subsequently, the characterisation of the remaining UGT2A enzyme, 
UGT2A2, was addressed (I, section 5.2). 
 13 
Table 1. UGT tissue expression. The table highlights the tissues that contain the highest mRNA  levels of a 
 given UGT enzyme. Other expression tissues besides the ones listed also exist. (Court et al., 2008; 
 Court et al., 2012; Ohno and Nakajin, 2009)  
UGT Tissue 
UGT1A1 Liver, small intestine 
UGT1A3 Liver, small intestine, colon 
UGT1A4 Liver, small intestine, colon  trachea, kidney 
UGT1A5 Liver, small intestine, colon, trachea 
UGT1A6 Liver, stomach, small intestine, colon, trachea, kidney, nasal 
epithelium 
UGT1A7 Liver, small intestine, colon, esophagus, kidney 
UGT1A8 Small intestine, colon, adrenal gland, nasal epithelium 
UGT1A9 Liver, small intestine, colon, kidney 
UGT1A10 Small intestine, colon, adipose tissue, nasal epithelium 
UGT2A1 Nasal epithelium 
UGT2A2 Nasal epithelium 
UGT2A3 Liver, small intestine, colon, adipose tissue 
UGT2B4 Liver, colon 
UGT2B7 Liver, small intestine, pancreas, kidney, uterus 
UGT2B10 Liver, testes 
UGT2B11 Liver, kidney, breast, prostate 
UGT2B15 Liver, stomach, breast, prostate 
UGT2B17 Liver, stomach, small intestine, colon,  pancreas, adipose tissue, 
testes, nasal epithelium 
UGT2B28 Liver 
 
 
Contrary to CYPs, the complete crystal structure of any UGT is yet to be solved and only 
a partial crystal structure of the UDPGA binding domain of UGT2B7 is available (Miley 
et al., 2007). In addition, several computational models of UGTs have also been made 
based on the known 3D structure of related bacterial and plant sugar transferases 
(Fujiwara et al., 2009; Laakkonen and Finel, 2010; Li and Wu, 2007). The lack of high 
resolution 3D structure of any full size UGT hinders the utilization of computational 
approaches in glucuronidation studies, for example at early stages of drug development. 
This highlights the importance of in vitro assays in predicting UGT catalysed metabolism. 
 
It has been postulated that UGTs function as dimers, based on different biochemical 
techniques, like co-immunoprecipitation, rescue of the activity of mutants, inhibition of 
activity by the alternative spliced variants, fluorescence energy transfer and others. There 
 14 
is evidence of both homo- and heterodimerisation; also with the alternative splice variants. 
(Bellemare et al., 2010; Finel and Kurkela, 2008; Fujiwara et al., 2010; Kurkela et al., 
2003; Meech and Mackenzie, 1997; Operana and Tukey, 2007). The proposed membrane 
topology of dimeric UGT is presented schematically in Figure 2. Most of the polypeptide, 
including the enzymes active site, resides in the ER lumen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Schematic representation of dimeric UGT topology at ER membrane. Most of the polypeptide Figure 2.
 resides in the ER lumen. (Adapted from Finel and Kurkela, 2008) 
UGTs catalyse the transfer of glucuronic acid from uridine 5?-diphosphoglucuronic acid 
(UDPGA) to various exo- and endogenous compounds. These substrate molecules are 
commonly regarded as aglycones (nonsugars) in comparison to glucuronides that contain 
the transferred glucuronic acid. Glucuronidation is evidently an SN2 type bimolecular 
nucleophilic substitution and the conjugation site is typically a hydroxyl-, carboxyl- or 
amino-group of the aglycone substrate. (Miley et al., 2007; Meech and Mackenzie, 1998; 
Patana et al., 2008). The proposed reaction mechanism is shown in Figure 3. The formed 
glucuronides are usually, but not always, biologically inactive and more hydrophilic than 
the corresponding aglycones. 
CYTOSOL 
ER LUMEN 
COOH COOH 
NH2 NH2 
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 SN2 type reaction mechanism of glucuronidation. The aglycone (R-OH) is deprotonated by the Figure 3.
 catalytic dyad of aspartic acid and histidine followed by the nucleophilic attack on C1 carbon of 
 UDPGA by the aglycone ion leading to the detachment of UDP. Protonated histidine is stabilized 
 by the neighboring aspartic acid.  (Miley et al., 2007; Yin et al., 1994) 
2.2 BILIRUBIN METABOLISM AND FAMILIAL HYPERBILIRUBINEMIAS 
 
In adults, approximately 250-350 mg of bilirubin is produced daily, mainly through the 
catabolism of heme proteins. Normal plasma concentration of bilirubin in human adults is 
5-15 µM. Neonates, however, can have significantly higher concentrations (up to 170 µM) 
of bilirubin during their first few weeks of life due to immature hepatic conjugation of 
bilirubin and a limited ability to transport it (Dennery et al., 2001; Kirkby and Adin, 
2006). The physiological condition associated with an excess amount of bilirubin is 
referred to as hyperbilirubinemia, and it is most visibly characterized by jaundice caused 
by the yellow pigmented colour of bilirubin. A small number of hyperbilirubinemias are 
due to a rare familial condition called Crigler-Najjar syndrome (CN). 
  
In the following chapters, the metabolism of bilirubin will be discussed, in addition to the 
mechanisms triggering Crigler-Najjar syndrome and the more common benign condition 
called Gilbert syndrome (GS). The pharmacological implications of hyperbilirubinemias 
and different therapeutical approaches to the treatment of CN will be taken into 
consideration. 
2.2.1 Bilirubin: properties and metabolism 
The main source of bilirubin is the breakdown of haemoglobin from red blood cells in the 
spleen. Heme is degraded by heme oxygenase, resulting in the release of iron and the 
formation of carbon monoxide and biliverdin (Tenhunen et al., 1969). Biliverdin is then 
further reduced to bilirubin by biliverdin reductase (Tenhunen et al., 1970).  
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Bilirubin is a linear tetrapyrrole featuring Z,Z configuration (Fig. 4). At physiological pH 
it has six intermolecular hydrogen bonds which stabilize the Z,Z configuration of bilirubin 
and prevent its interactions with polar groups in aqueous milieu. Therefore bilirubin is 
very lipophilic with a logP value of approximately 5 (U.S. National Library of Medicine).  
NH
O
NH
O
O
HN
HN
O
H
O
OH
HNNH
NH
O
HN
O
OH
O
HO
O
 
 Bilirubin Structure. Bilirubin in its linear Z,Z conformation (A) and ridge tile conformation (B). In Figure 4.
 ridge tile conformation each propionic acid group has a hydrogen bond with the opposing 
 dipyrrinone lactam and pyrrole (Boiadjiev and Lightner, 2001). 
Hydrophobicity is the main reason behind the toxic effects of bilirubin. Due to its high 
hydrophobicity, bilirubin can passively diffuse across biological membranes, including the 
blood-brain barrier, if it is not bound to albumin or if it is unconjugated, namely without 
any glucuronic acid (Zucker et al., 1999). In the central nervous system, bilirubin exhibits 
considerable toxicity to neurons, including the inhibition of protein kinase C, an essential 
enzyme for synaptic signalling (Grojean et al., 2000). In vivo and in vitro experiments 
have also indicated that bilirubin induces apoptosis (Grojean et al., 2000; Grojean et al., 
2001; McDonald et al., 1998). The mode of apoptosis is apparently mitochondria 
mediated: bilirubin diffuses across mitochondrial membranes, causing mitochondrial 
swelling and the release of cytochrome c to the cytosol, triggering apoptosis (Rodrigues et 
al., 2000). It has also been shown that even a short time exposure of neurons to bilirubin 
can inhibit their function (Zhang et al., 2003). 
 
Due to this hydrophobicity, bilirubin cannot be excreted as it is and must be modified 
enzymatically first (Kirkby and Adin, 2006; Boiadjiev and Lightner, 2001). Bilirubin has 
high affinity to albumin and over 99% of unconjugated bilirubin circulates in the plasma 
A B 
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bound to albumin (Ostrow et al., 2003). Unconjugated and albumin-bound bilirubin is 
transported to the liver, where it dissociates from albumin and moves into hepatocytes 
either by diffusion or active uptake (Tiribelli and Ostrow, 1996). Inside hepatocytes, 
UGT1A1 catalyses the transfer of glucuronic acid from UDPGA to the carboxylic groups 
of bilirubin to form mono- and di-glucuronides. Of the known 19 UGT isoforms, only 
UGT1A1 is capable of glucuronidating bilirubin (Bosma et al., 1994). Bilirubin 
glucuronides are excreted into bile via the efflux transporter ABCC2 (MRP2) and, 
eventually, into the intestine (Paulusma et al., 1997). 
2.2.2 Gilbert syndrome 
Gilbert syndrome, a common and benign familial hyperbilirubinemia, was first described 
over a hundred years ago (Gilbert and Lereboulet, 1901). Estimations about the prevalence 
of GS in the Caucasian population vary between 6 and 16% (Monaghan et al., 1996; 
Owens and Evans, 1975). Patients with GS have approximately 30% of UGT1A1 activity 
compared to normal UGT1A1 activity and this causes slightly elevated, usually 15-50 ?M, 
serum bilirubin levels and, in some cases, mild jaundice (Monaghan et al., 1996, Burchell 
and Hume, 1999). The condition, however, is benign and requires no treatment. 
 
Today there are 19 mutations reported in the literature causing GS (see Canu et al., 2013 
for a recent review). In the Caucasian and African populations the most common mutation 
is the elongation of a TATA-box in the promoter region of UGT1A1 by an additional TA 
repeat. This is also known as UGT1A1*28 polymorphism or A(TA)7TAA and it causes 
underexpression of UGT1A1 (Bosma et al., 1995). This polymorphism has approximately 
40% frequency in these populations, but only 16% in Asian populations (Beutler et al., 
1998). In Asian populations the missense mutation G71R (UGT1A1*6) is also a 
significant cause of GS (Akaba et al., 1998). 
 
Although GS is benign, it may have clinical significance. While bilirubin is traditionally 
considered to be a metabolic waste product, it also has antioxidant capacity and it has been 
shown to prevent the oxidation of lipids and lipoproteins (Stocker et al., 1987; Sedlak et 
al., 2009). The antioxidant properties of bilirubin are directly related to the total serum 
antioxidant capacity and several studies have associated either low bilirubin levels with 
higher risk, and/or high bilirubin levels with lower risk, of cardiovascular diseases 
(Horsfall et al., 2012; Kimm et al., 2009; Perlstein et al., 2008; Rantner et al., 2008; Vitek 
et al., 2002). The actual mechanism behind this association is not entirely clear and not all 
studies have associated the UGT1A1*28 mutation with decreased risk of cardiovascular 
diseases (Rantner et al., 2008; Hsieh et al., 2008). 
 
GS has also been associated with increased risk of certain cancers. The UGT1A1*6 
genotype has been associated with the risk of developing colorectal cancer in a case 
control study with Chinese patients (Tong et al., 2007). The UGT1A1*28 genotype, on the 
other hand, has been linked to both decreased (Jiraskova et al., 2012) and increased (Bajro 
et al., 2012) risk of colorectal cancer in males. The case control studies of UGT1A1*28 
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and the risk of breast cancer are also conflicting. Some analyses have associated 
UGT1A1*28 genotype with increased risk of breast cancer (Shatalova et al., 2006; 
Adegoke et al., 2004), while others failed to find a significant association (Guillemette et 
al., 2001). 
 
UGT1A1 has numerous other endobiotic and xenobiotic substrates besides bilirubin, 
including steroid hormones and drugs. Reduced UGT1A1 function may potentially affect 
the metabolism of these compounds, too. The best known example is irinotecan, a pro-
drug that is used in the treatment of metastatic colorectal cancer. Irinotecan is converted 
by endogenous carboxyesterase enzymes to the active metabolite, SN-38, that is a 
topoisomerase I inhibitor. SN-38 is glucuronidated by UGT1A1 to an inactive glucuronide 
and failure to do this may cause severe drug toxicity (Iyer et al., 1998). Patients with GS 
have been shown to have an increased risk of SN-38 mediated toxicity, especially at high 
irinotecan doses. Due to this, in 2005 the US Food and Drug Administration (FDA) 
recommended UGT1A1*28 testing on the irinotecan drug label (Marques and Ikediobi, 
2010).  
2.2.3 Crigler-Najjar syndromes 
Cricler-Najjar syndrome is a familial hyperbilirubinemia that was first described by John 
Fielding Crigler and Victor Assad Najjar in 1952 (Crigler and Najjar, 1952). Crigler and 
Najjar, who also gave their name to the syndrome, described six children born to three 
different families that suffered from severe unconjugated hyperbilirubinemia. Five of 
these children died before reaching 15 months of age and one lived up to be 15 years old. 
It was concluded that the children had died of brain damage caused by kernicterus. 
 
Later it was found that there is variation in the severity of hyperbilirubinemia between CN 
patients and the syndrome was divided into two clinically distinct forms: CN type I (CN-I) 
and CN type II (CN-II) (Arias et al., 1969). CN-I patients do not have any bilirubin 
conjugation activity and their serum bilirubin levels vary between 340-685 µM (normal 
range 5-15 ?M). CN-II patients, on the other hand, have some bilirubin glucuronidation 
activity left and their serum bilirubin levels range from 100 to 340 µM (Costa, 2006). The 
distinction between GS, CN-II, and CN-I is not sharp and there is a continuous spectrum 
in the severity of hyperbilirubinemia (Fig. 5). 
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 Graphic representation of UGT1A1 activity and its correlation to familial hyperbilirubinemias Figure 5.
 Gilbert syndrome (GS) and Crigler-Najjar syndromes I and II (CN-I and CN-II, respectively). 
 (Adapted from Strassburg, 2010) 
The residual bilirubin glucuronidation activity can be further enhanced with phenobarbital 
treatment. Response to phenobarbital treatment can also be used to distinguish between 
the two syndromes: While CN-I patients do not response to the treatment, CN-II patients 
response to the treatment and their serum bilirubin levels are reduced due to phenobarbital 
induced glucuronidation (Arias et al., 1969). Type II CN can, however, also lead to 
kernicterus and irreversible neurological damage, for example post surgically, or if the 
syndrome is severe (Poddar et al., 2002; Thapa et al., 1987; Chalasani et al., 1997) 
 
Today CN syndrome is known to be caused by deficiency in UGT1A1 function (Bosma et 
al., 1992) and there are at least 102 mutations causing CN syndrome reported in the 
literature. Mutations have been found in all five exons of UGT1A1 and also in the splice 
sites and they include point mutations, deletions, and insertions (see Canu et al., 2013 for a 
recent review). CN syndromes are inherited recessively and are estimated to affect 1/106 
new-borns (Bosma, 2003). In some cases, however, the inheritance seems dominant with 
incomplete penetrance. This might be the case, for example, if the patient is heterozygous 
for CN-I type mutation and homozygous for GS type promoter mutation (Chalasani et al., 
1997).  
 
Insufficient bilirubin conjugation in CN patients leads to accumulation of unconjugated 
bilirubin in the serum and hyperbilirubinemia. In concentrations over 200-300 µM, serum 
albumin binding becomes saturated and concentrations of free, unbound, bilirubin rise 
drastically. Toxic levels of bilirubin are therefore reached at these concentrations 
(Wennberg, 2000). 
 
There is a natural mutant rat model, the Gunn rat, for CN syndrome (Gunn, 1944). Gunn 
rats have a deletion at nucleotide 1242 of bilirubin glucuronidating UGT, which results in 
a frameshift mutation and a premature stop codon (Sato et al., 1991). This rat model has 
proven to be useful in various studies of CN syndrome, including demonstration that CN 
syndrome is caused by deficient bilirubin glucuronidation (Axelrod et al., 1957). A mouse 
model for CN has also been introduced recently (Nguyen et al., 2008). 
 
UGT1A1 Activity 
Hyperbilirubinemia 
100 % 0 % 
Phenotype:                                   GS        CN-II                                  CN-I 
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2.2.3.1 Current therapy for Crigler-Najjar syndrome 
CN-II patients do retain some UGT1A1 activity and their condition is usually more easily 
treatable compared to CN-I patients. The treatment of CN-II patients typically consists of 
UGT1A1 inducer phenobarbital (Arias et al., 1969). Some CN-II patients, however, also 
require phototherapy or even a liver transplant (II, V). 
 
The absence of bilirubin glucuronidation activity is fatal for humans and before the 
development of phototherapy, CN-I was a lethal disease (Crigler and Najjar, 1952). 
Nowadays CN syndromes are treatable and the patients can reach adulthood without 
irreversible brain damage (van der Veere et al., 1996). The discovery of phototherapy 
greatly improved the prognosis for CN-I and it remains the most prevalent treatment for 
CN syndromes (Bosma, 2003; van der Veere et al., 1996; Cremer et al., 1958). The 
effectiveness of phototherapy is based on the ability of blue light to convert bilirubin from 
its 4Z,15Z configuration to different photoisomers, e.g. to 4E,15Z-cyclobilirubin. These 
photoisomers are not able to compose as many intramolecular hydrogen bonds as 
physiological bilirubin and are therefore more hydrophilic and easily excretable (Lightner 
et al., 1979). Phototherapy is, however, cumbersome and it affects the life quality of CN-I 
patients, considering that some of them may need phototherapy up to 14 hours per day. 
Another drawback of phototherapy is that it usually becomes less effective as patients age 
due to the thickening of the skin, and the risk of bilirubin encephalopathy therefore 
increases with age (van der Veere et al., 1996). The only permanent therapy for CN-I 
patients in the long term is liver transplantation and usually CN-I patients will need the 
liver transplant at some point in their lives, when phototherapy is no longer effective 
enough to maintain safe bilirubin levels (van der Veere et al., 1996). Since only a small 
amount of liver is needed for a sufficient amount of glucuronidation, auxiliary liver 
transplantation has also proven to be effective (Rela et al., 1999). 
 
Since there are difficulties with both phototherapy and liver transplantation, namely the 
lack of organ donors and side effects of lifelong immune suppression, there is a 
substantive need for alternative treatments for CN-I. Hepatocyte transplantation has been 
one of the more recent approaches that have been carried out in CN patients (Fox et al., 
1998). Nonetheless, hepatocyte transplantation has thus far yielded only a partial lowering 
of bilirubin levels and the results have persisted for less than one year in most cases (Lysy 
et al., 2008). 
2.2.3.2 Gene therapy in treatment of Crigler-Najjar syndrome 
Gene therapy is another new approach for CN treatment. The syndrome has many 
characteristics that make it an ideal disease for gene therapy treatment. It is caused by a 
single gene and for therapeutic effect it is sufficient if approximately 5% of UGT1A1 
activity is regained (Fox et al., 1998). Moreover, there is an animal model, the Gunn rat, 
available for preclinical trials. The efficacy of the treatment in human patients, however, 
cannot be monitored by serum bilirubin quantification, since CN-I patients need daily 
phototherapy. Therefore it is impossible to determine whether the serum bilirubin is 
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lowered because of phototherapy or as a consequence of gene therapy. This issue is 
addressed in publication V. 
 
Several groups have succeeded in lowering bilirubin levels in vivo in Gunn rats by hepatic 
gene transfer of the UGT1A1. Various different vectors have been used, including plasmid 
DNA (pDNA) (Jia and Danko, 2005a; Jia and Danko, 2005b), retrovirus based viral 
vectors (Bellodi-Privato et al., 2005), lentiviral vectors (Nguyen et al., 2007; Seppen et al., 
2006; Schmitt et al., 2010), recombinant simian virus 40 (SV40) vectors (Sauter et al., 
2000), adenovirus vectors (Askari et al., 1996; Dimmock et al., 2011; Toietta et al., 2005), 
and adeno-associated virus vectors (AAV) (Seppen et al., 2006; Pastore et al., 2012; 
Montenegro-Miranda et al., 2011). AAV vectors have been shown to be effective also in 
the  treatment  of  CN in  a  mouse  model  (Bortolussi  et  al.,  2012).  In  many cases,  a  single  
dose of a vector may provide a lifelong correction of bilirubin levels (Nguyen et al., 2007; 
Seppen et al., 2006; Toietta et al., 2005; Bortolussi et al., 2012). 
 
AAV  vectors  (Fig.  6)  are  among  the  most  promising  vector  systems  for  gene  therapy.  
They are non-pathogenic (lack all viral genes), have a broad host spectrum, are stable, and 
maintain a high level of expression for a long time. Recombinant AAV vectors that are 
used in gene transfer contain the desired gene and suitable promoter or enhancer element, 
flanked by two inverted terminal repeats (ITR). ITRs facilitate hairpin-type intrastrand 
base pairing which enables self-priming in DNA replication. A recombinant AAV also 
needs rep and cap genes and a helper virus for its replication and integration to the 
genome. These elements are usually provided in trans. (Grieger and Samulski, 2012) 
 
AAV transduction is a multistep process including attachment to cell membrane, virion 
internalization, intracellular trafficking, and transport to the nucleus (Buning et al., 2008).  
Before transduction to the genome, AAV vectors need to be converted from single to 
double stranded, which is the rate limiting step of AAV mediated transduction (Ferrari et 
al., 1996). Self-complementary AAVs (scAAV) vectors circumvent the problem by having 
a dimeric inverted repeat sequence. A mutated ITR at the middle of the sequence forms a 
closed hairpin structure at one end of the self-complementary sequence while wild-type 
ITRs  form  two  hairpins  at  the  open  end.  With  the  rate  limiting  step  bypassed,  scAAV  
vectors have been shown to have higher transduction efficiencies than conventional AAV 
vectors (McCarty et al., 2001). 
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 Schematic figure of wild type and recombinant AAV genomes. Wild type AAV (A) contains rep Figure 6.
 and cap regions flanked by inverted terminal repeats (ITRs). Recombinant AAV (B) contains gene 
 of interest and suitable promoter or enhancer element in place of rep and cap regions. Recombinant 
 AAVs however need trans helper system containing rep and cap genes. scAAV vectors (C) contain 
 mutated ITR in the middle of the sequence, which forms a closed hairpin structure at one end of the 
 dimeric inverted sequence. Wild type ITRs form two hairpins at the other end. 
2.3 STEROID HORMONES AND THEIR METABOLISM 
 
Steroids are a large class of generally lipophilic compounds, with a core structure of four 
rings  of  17  carbons  (Fig.  7).  They  are  formed  from  cholesterol  in  a  process  called  
steroidogenesis and they differ from each other by functional groups attached to the 
carbon rings and by the oxidation state of the rings. 
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 Carbon atom and ring numbering of steroids. Gonane, the simplest possible steroid, is presented in Figure 7.
 2D and 3D structure. 
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Steroidogenesis takes place mainly in the adrenal cortex, testes, ovaries, and in the 
placenta during pregnancy. Numerous different enzymes are involved in the production of 
steroids, many of them CYP enzymes (Hanukoglu, 1992). Metabolism of endogenous 
estrogens is presented in Figure 8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Endogenous metabolism of estrogens. Estrone and estradiol are generated from androstenedione Figure 8.
 and testosterone, respectively. Estriol is mainly generated from estradiol and estrone, but it can also 
 arise from 16-hydroxyandrostenedione (16-OH AD), or from 16-hydroxydehydroepiandrosterone 
 (16-OH DHEA). Estriol stereoisomers, 17-epiestriol and 16-epiestriol, are formed from 16?-
 hydroxyestrone or estriol in subsequent reduction and oxidation reactions (Eliassen et al., 2009). 
 The natural estrogens studied in publications I-III and VI are highlighted.  
Enantiomeric steroids (ent-steroids) have opposite configurations at all chiral centres in 
comparison to their corresponding natural steroid, resulting in a mirror image of the 
molecule (Fig. 9). Enantiomers have identical chemical and physical properties, except for 
their ability to rotate plane-polarized light. Their three-dimensional structures, on the other 
hand,  are  different  and  this  may result  in  different  types  of  binding  in  different  types  of  
binding pockets. Enantiomeric structures are interesting starting points for drug discovery 
 
O
OH
OH
OH
OH
O
OH
OH
OH
OH
OH
OH
OH
OH
OH
OH
OH
O
OH
 
Estrone 17?-Estradiol 
16?-Hydroxyestrone 
Estriol 
16-Ketoestradiol 
Catechol estrogens 
16-OH AD and 
16-OH DHEA  
 
 
17-epiestriol 
16-epiestriol 
Androstenedione Testosterone 
I, II, III, VI 
I, III, VI 
Publication
s 
VI 
 24 
because the stereochemical changes of the parent molecule can drastically affect the 
pharmacological properties of the molecules. 
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H H
H
OH
H H
H
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 17?-estradiol (A) with its enantiomer, ent-estradiol (B).  Figure 9.
The clinical potential of ent-steroids has been studied for several years (reviewed by 
Covey, 2009). Some ent-steroids, like ent-estradiol and ent-progesterone, have been 
shown to have neuroprotective effects (Green et al., 2001; VanLandingham et al., 2006). 
Ent-androsterone and ent-etiocholanolone have also been shown to be positive allosteric 
modulators of ?-aminobutyric acid (GABA) type A receptors and to be substantially more 
active on them than their natural counterparts (Katona et al., 2008; Krishnan et al., 2012). 
2.3.1 Glucuronidation of steroid hormones 
It is commonly believed that one of the major functions of UGTs is the glucuronidation of 
steroids. UGTs can conjugate the naturally occurring steroid hydroxyl groups or the 
hydroxyl groups gained though catabolism. Conjugated steroids have a significantly 
reduced or non-existent ability to bind to steroid receptors, and to generate biological 
response (You, 2004). Glucuronidated steroids are also more readily removed from the 
tissue and more easily excretable in urine than their corresponding aglycones. Many 
steroid glucuronides are indeed detectable in urine (Smith and Kellie, 1967; Kirdani et al., 
1977).  
 
Alongside  sulfotransferases  (SULTs)  and  CYPs,  UGTs  are  one  of  the  major  enzyme  
families involved in steroid catabolism (You, 2004). As ‘high affinity, low activity’ 
enzymes, SULTs are effective in conjugating steroids at low concentrations. The 
importance of UGTs is emphasized at high steroid concentrations, as the capacity of 
SULTs is saturated and the ‘low affinity, high capacity’ UGTs step in.  
 
Estradiol (E2) glucuronides were discovered as early as 1936 when Cohen and Marrian 
reported estrogen glucuronides from human pregnancy urine (Cohen and Marrian, 1936). 
Since then, several steroids have been found to be UGT substrates and steroid 
glucuronidation has also been studied extensively in vitro. (Table 2)  
 
A B 
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Table 2. Selected UGT steroid hormone substrates and their major glucuronidating UGT enzymes. 
Trivial name Structure 
Major 
glucuronidating 
enzymes 
Reference 
Estrone (E1) 
 H
H
H
O
OH  
1A1, 1A8, 
1A10 
(Smith and Kellie, 
1967; Lepine et al., 
2004) 
Estradiol (E2) 
 H
H
H
OH
OH  
UGT1A1, 
UGT1A10, 
UGT2B7, 
UGT2B17 
(Smith and Kellie, 
1967; Itaaho et al., 
2008) 
 
Estriol (E3) 
 H
H
H
OH
OH
OH
 
UGT1A10, 
UGT2B7 
(Sandberg and 
Slaunwhite, 1965, VI) 
Testosterone 
H
H
H
OH
O  
UGT2A1, 
UGT2B15, 
UGT2B17 
(Fishman and Sie, 
1956; Sten et al., 
2009a) 
Dihydro-
testosterone 
(DHT) 
O
H
H
OH
HH
 
UGT2B15, 
UGT2B17 
(Kirdani et al., 1977; 
Murai et al., 2006) 
Androsterone 
H
H
H
O
OH
H  
UGT2B7, 
UGT2B17 
(Coffman et al., 1998; 
Sten et al., 2009b) 
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Several UGT enzymes are capable of steroid glucuronidation. Generally, UGT1A 
enzymes are known to glucuronidate estrogens E1, E2, E3 and catechol estrogens (Lepine 
et al., 2004; Itaaho et al., 2008; Starlard-Davenport et al., 2007, VI). The extrahepatic 
UGT1A10 seems to be the major UGT isoform in conjugation of estrogens at the 3-OH 
position and it has also been shown to be up-regulated by E2 in breast cancer cells 
(Starlard-Davenport et al., 2008b). UGT2Bs, on the other hand, generally catalyse 
estrogen glucuronidation at D-ring, as well as glucuronidation of androgens that lack the 
phenolic 3-OH (Sten et al., 2009b; Sten et al., 2009a; Chouinard et al., 2008). Especially 
UGT2B7 and UGT2B17 have high capacities for androgen conjugation. UGT2B7 seems 
to be able to glucuronidate most steroids, including estrogens (Itaaho et al., 2008; 
Radominska-Pandya et al., 2001). Interestingly, UGT1As and 2Bs exhibit stereoselectivity 
in estrogen glucuronidation. UGT1As, with the exception of 1A3 and 1A4, generally 
catalyse the conjugation of 3-hydroxyl of estrogens, while UGT2Bs, with the exception of 
2B15, glucuronidate D-ring hydroxyls (Itaaho et al., 2008, VI). 
 
The nasal epithelium enzymes UGT2A1 and UGT2A2 have exceptionally broad substrate 
specificity, even for UGTs, and their substrates include many estrogens and androgens 
(Jedlitschky et al., 1999; Sten et al., 2009b; Sten et al., 2009a, I). UGT2A1 and UGT2A2 
also exhibit less stereoselectivity and they are often capable of glucuronidating both A and 
D ring hydroxyls of steroids, but at different rates (Itaaho et al., 2008, VI). 
 
Steroids have been shown to be glucuronidated in steroid target tissues (Chung and 
Coffey, 1978; Adams et al., 1989) and steroid glucuronides have also been found in 
several of these tissues, including prostate, breast cyst fluid, and ovary follicular fluid 
(Belanger et al., 1991). Expression of UGTs, determined by mRNA levels, has also been 
documented in these tissues and especially many UGT2B enzymes are expressed in 
steroidogenic tissues (Table 1). Based on the abundance of UGTs in steroidogenic tissues 
and the evidence of their glucuronidation in situ, it is proposed that UGTs are involved in 
maintaining steroid homeostasis via glucuronidation in steroid target tissues. Human 
prostate adenocarcinoma LNCaP cells expressing UGT2B17 have been found to have 
decreased response to androgens, which suggests that glucuronidation plays a role in 
regulating the availability of steroids at their target sites (Belanger et al., 1998). 
 
The metabolic pathways of enantiomeric steroids are poorly characterised and in 
publication IV, how these molecules are glucuronidated compared to their natural 
counterparts was investigated for the first time. 
2.3.2 Steroids and health 
Steroids are known to be involved in normal physiology and several medical conditions, 
especially in cancers that are located in steroid target tissues. For example, increased 
steroid concentrations have been associated with higher risk of breast cancer in 
postmenopausal women, (Key et al., 2002) and in some studies also among 
premenopausal women (Walker et al., 2011). In estrogen dependent cancers, the activation 
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of estrogen receptors induces the growth of cancer cells. These cancers can be treated by 
blocking estrogen receptors with antiestrogens, such as tamoxifen, in the case of breast 
cancer (Cuzick et al., 2013). Enantiomeric steroids were initially considered potential 
antiestrogens, but later found to bind only weakly to estrogen receptors and also to lack 
estrogenic effects in murine tissues (Payne and Katzenellenbogen, 1979). 
 
The 4-hydroxylated estrogens have also been associated with breast cancer (Liehr and 
Ricci, 1996). In normal breast tissue, 2-hydroxyestradiol is the dominant catechol 
estrogen, but in breast cancer cells 4-hydroxyestradiol predominates. Both of these 
hydroxylated estradiols can form reactive quinones that can bind to DNA and lead to 
mutations and eventually induce cancer (Cavalieri et al., 2002; Stack et al., 1996). The 2-
hydroxyestradiol is apparently less carcinogenic, since the 2,3-quinone formed from 2-
hydroxyestradiol is less reactive than the corresponding 3,4-quinone formed from 4-
hydroxyestradiol. The 2-hydroxyestradiol also forms smaller amount of these reactive 
quinones since it is methylated by catechol-O-methyltransferase (COMT) at higher rates 
than 4-hydroxyestradiol (Emons et al., 1987; Zahid et al., 2006). An elevated ratio of 4-/2-
hydroxyestradiol formation is therefore suggested to be a biomarker of benign or 
malignant breast tumours (Liehr and Ricci, 1996). Besides COMT, UGTs are also capable 
of inactivating these catechol estrogens, and thus may protect cells from the carcinogenic 
effects of them (Raftogianis et al., 2000). 
  
Some studies have also associated higher testosterone levels with increased risk for 
prostate cancer (Hyde et al., 2012). Taken together, it is postulated that the 
glucuronidation of steroids could prevent the possibly carcinogenic effects of altered 
steroid concentrations. Although this is an exciting concept, there is little evidence of this 
actually being the case. This may be partly due to the fact that steroids have other 
catabolic routes besides glucuronidation and also because UGTs show extensive 
overlapping in substrate specificity. That is, if a given UGT enzyme has impaired activity, 
other UGTs can compensate for it in many cases. 
 
Although correlation between steroid glucuronidation and diseases is less clear than with 
UGT1A1 and hyperbilirubinemias, there is some clinical evidence available, especially 
concerning cancers. A whole gene deletion of UGT2B17 (UGT2B17*2) has been reported 
in humans and the frequency of this polymorphism is about 11% in Caucasians and 2% in 
African Americans (Wilson et al., 2004). Individuals homozygous for this deletion have 
been associated with increased prostate cancer risk in the Caucasian, but not in the African 
American population (Park et al., 2006). Several opposite results, with no such correlation, 
have also been reported (Gallagher et al., 2007; Olsson et al., 2008; Setlur et al., 2010), so 
this correlation remains controversial. 
 
UGT2B15 is also polymorphic, and the allele UGT2B15(Y85) (UGT2B15*2) has higher 
Vmax values for dihydrotestosterone glucuronidation than the wild type UGT2B15(D85) 
(Levesque et al., 1997). Several studies have associated the lower activity allele D85 with 
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increased risk of prostate cancer (MacLeod et al., 2000; Park et al., 2004; Okugi et al., 
2006; Grant et al., 2013), while others have failed to find any correlation (Cunningham et 
al., 2007; Gsur et al., 2002). 
 
UGT1A enzymes may also be involved in abnormal estrogen glucuronidation among 
breast cancer patients. The glucuronidation of 4-hydroxyestrone has been shown to be 
significantly reduced in cancer breast tissue, with a concomitant reduced expression of 
UGT1A10 (African American women) and UGT2B7 (Caucasian women) (Starlard-
Davenport et al., 2008a). 
 
Association between endometrial cancers and certain UGT1A1 and UGT2B7 
polymorphisms has also been investigated. The results of this study indicated that UGT 
polymorphisms do not contribute to the risk of endometrial cancer (McGrath et al., 2009). 
As discussed in section 2.2.2, the role of UGT1A1*28 polymorphism in the risk of breast 
cancer and colorectal cancer remains controversial. 
2.4 STEROID GLUCURONIDATION AND UGT STRUCTURE 
 
As mentioned before, the high-resolution crystal structure of any UGT is yet to be solved. 
Therefore,  the  substrate  specificity  of  a  given  UGT is  difficult,  or  impossible  to  predict,  
although this kind of information would often be very useful in drug development. Instead 
many other approaches have been made in trying to determine the critical amino acids and 
the structure of UGTs and their binding sites. These approaches include molecular 
modelling, site directed mutagenesis, chimerisation, pharmacophore models, and 
structure-activity studies (Laakkonen and Finel, 2010; Xiong et al., 2006; Itaaho et al., 
2010; Smith et al., 2003). 
 
As relatively large and rigid molecules, steroids are prospective candidates in determining 
UGT structure via function. Examining the different configurations of the hydroxyl groups 
on rings A and D provides insight into the binding of steroids to the UGT active site and 
the possible binding to critical amino acid residues. This approach is used in publication 
VI, where in addition to novel information on substrate specificity, some basic ideas of 
differences in the active sites between individual UGT enzymes could be drawn.  
 
Combining this strategy with site directed mutagenesis adds value to this approach and 
even enables the making of molecular models that are based on the obtained information. 
This approach was employed in publication III where a molecular model of the UGT1A10 
binding site was built based on the information gained from estrogen glucuronidation 
studies with two UGT1A10 mutants.  
 
Some of the differences observed in the glucuronidation of different steroids may be due 
to their different physiochemical properties rather than three-dimensional structure. 
Enantiomeric steroids, on the other hand, are interesting in this area since they have the 
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same physicochemical properties as the corresponding endogenous steroids, and therefore 
any differences between the glucuronidation of enantiomers and their natural counterparts 
are solely due to the differences in three-dimensional shape. Enantiomeric steroids were 
used as study tools in publication IV. 
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3. AIMS OF THE STUDY 
a) To investigate the UGT1A1 missense mutant enzymes found in Dutch Crigler-
Najjar patients and to work with the development of gene therapy treatment for the 
syndrome (II, V).  
 
A functional analysis of the missense mutant UGT1A1 enzymes was pursued by 
expressing 10 missense mutants and wild type UGT1A1 in baculovirus-infected insect 
cells and microsomal preparations were made of them. The glucuronidation activity of the 
mutants with bilirubin was then studied in order to estimate the correlation of genotype 
and phenotype (the severity of hyperbilirubinemia). Furthermore, other substrates were 
tested with the mutants to see whether the mutations would lead to any unexpected 
activity, which would be interesting for determining the structure of UGT active site. 
 
Promising results for CN-I gene therapy in Gunn rats, the animal model for the disease, 
have been reported by our collaborator Dr. Piter Bosma and his team (Liver Center of the 
Academical Medical Center of the University of Amsterdam). As part of this collaboration 
a nontoxic and specific bio-marker for this treatment was sought (V). It was anticipated 
that the glucuronide concentration of this biomarker would correlate with the recovery of 
UGT1A1 activity thereby confirming the efficacy of gene therapy treatment even under 
conditions of on-going phototherapy.  
 
b) To express and characterize the novel UGT enzyme UGT2A2 (I).  
 
The UGT2A2 gene had previously been found in the human genome and some mRNA 
expression reported in segments of the intestinal tract. A complete and thorough 
characterization was sought, including substrate specificity and a detailed tissue 
expression pattern. 
 
c) To study the glucuronidation of steroid hormones (III, IV, VI).  
 
The main goals were to extend and improve the picture of steroid glucuronidation and to 
determine UGT specific stereospecificities of the glucuronidation in order to help 
determine UGT structure via function. Site specific mutations (III) and enantiomeric 
steroids (IV) were also used to gain more detailed information. 
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4. MATERIALS AND METHODS 
4.1 MATERIALS 
4.1.1. Chemicals 
The chemicals that were used in publications I-VI are listed in Table 3. The chemicals 
were of analytical grade and the high performance liquid chromatography (HPLC) eluents 
were of HPLC grade or mass spectrometry (MS) grade, when LC-MS was used.  The ent-
androsterone, ent-etiocholanolone, ent-17?-estradiol, and 13-epiestradiol were synthesized 
in the laboratory of Prof. Douglas Covey according to methods that are described 
elsewhere (Green et al., 2001; Katona et al., 2008; Ayan et al., 2011). 1-hydroxypyrene ?-
D-glucuronide was synthesized in our laboratory as described earlier (Luukkanen et al., 
2001). 
Table 3. Chemicals used in this study. 
Chemical Supplier Use 
Publi-
cation 
Acetic acid J.T. Baker, Deventer, Netherlands HPLC I-III 
Acetonitrile Fluka, Germany HPLC I-VI 
Alamethicin Sigma-Aldrich, St. Louis, MO Activity assay V, VI 
4-Aminobiphenyl Sigma-Aldrich, St. Louis, MO Substrate I 
Ammonium acetate Riedel-de Haën, Seelze, Germany HPLC I, IV 
ent-Androsterone Prof. DF Covey, Washington 
University in St. Louis, School of 
Medicine, St. Louis, MO 
Substrate IV 
Bilirubin Sigma-Aldrich, St. Louis, MO Substrate II, V 
Deuterated methanol Sigma-Aldrich, St. Louis, MO NMR VI 
Dimethylsulfoxide Fluka, Germany Activity assay I-VI 
Disodium hydrogen 
phosphate dihydrate 
Fluka, Germany Activity assay I-VI 
Entacapone Orion Pharma, Espoo, Finland Substrate III 
13-Epiestradiol (18-
epiestradiol) 
Prof. DF Covey, Washington 
University in St. Louis, School of 
Medicine, St. Louis, MO 
Substrate VI 
17?-Estradiol Sigma-Aldrich, St. Louis, MO Substrate I-V 
ent-17?-Estradiol Prof. DF Covey, Washington 
University in St. Louis, School of 
Medicine, St. Louis, MO 
Substrate IV 
?-Estradiol 3-?-D-
glucuronide 
Sigma-Aldrich, St. Louis, MO Standard I-V 
?-Estradiol 17-?-D-
glucuronide 
Sigma-Aldrich, St. Louis, MO Standard I, II, IV 
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Table 3. Continued. 
 
16?, 17?-Estriol Sigma-Aldrich, St. Louis, MO Substrate VI 
16?, 17?-Estriol Sigma-Aldrich, St. Louis, MO Substrate I-III, VI 
16?, 17?-Estriol Steraloids, Newport, RI Substrate VI 
Estriol 3-?-D-
glucuronide 
Sigma-Aldrich, St. Louis, MO Standard I-III, VI 
Estriol 16?-?-D-
glucuronide, 
Sigma-Aldrich, St. Louis, MO Standard I, VI 
Estriol 17?-?-D-
glucuronide, 
Sigma-Aldrich, St. Louis, MO Standard VI 
17?-Ethinylestradiol Sigma-Aldrich, St. Louis, MO Substrate I-III, V 
ent-Etiocholanolone Prof. DF Covey, Washington 
University in St. Louis, School of 
Medicine, St. Louis, MO 
Substrate IV 
Ezetimibe Kemprotec Ltd, Middlesbrough, 
UK/MSD,Hertfordshire, UK 
Substrate V 
Formic acid 98-100% Sigma-Aldrich, St. Louis, MO HPLC V, VI 
7-Hydroxycoumarin 
?-D-glucuronide 
Ultrafine Synergy-House, 
Manchester, UK 
Standard I-III 
1-Hydroxypyrene Sigma-Aldrich, St. Louis, MO Substrate I, II 
1-Hydroxypyrene ?-D-
glucuronide 
Faculty of Pharmacy, University of 
Helsinki, Finland 
Standard I, II 
Hyodeoxycholic acid Sigma-Aldrich, St. Louis, MO Substrate I 
Methanol Fluka, Germany/Merck, Darmstadt, 
Germany 
Activity assay, 
HPLC 
I-VI 
4-
Methylumbelliferone 
Sigma-Aldrich, St. Louis, MO Substrate I-III 
4-Methylumbelliferyl 
?-D-glucuronide  
Sigma-Aldrich, St. Louis, MO Standard I-III 
MgCl2 Riedel-de Haën, Seelze, Germany Activity assay I-VI 
?-Naphthol Sigma-Aldrich, St. Louis, MO Substrate I-III 
?-Naphthyl ?-D-
glucuronide 
Sigma-Aldrich, St. Louis, MO Standard I-III 
4-Nitrophenol Sigma-Aldrich, St. Louis, MO Substrate I-III 
4-Nitrophenyl ?-D-
glucuronide 
Sigma-Aldrich, St. Louis, MO Standard I-III 
Perchloric acid 70-
72% 
Merck, Darmstadt, Germany Activity assay I-VI 
2-phenylphenol Fluka, Germany Substrate I 
3-phenylphenol Chiron Trondheim, Norway Substrate I 
4-phenylphenol Fluka, Germany Substrate I 
D-Saccharic acid 1, 4-
lactone 
Sigma-Aldrich, St. Louis, MO Activity assay I-III 
Scopoletin Sigma-Aldrich, St. Louis, MO Substrate I-III 
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Sodium phosphate 
monobasic dihydrate 
Sigma-Aldrich, St. Louis, MO Activity assay, 
HPLC 
I-VI 
Testosterone-
glucuronide 
National Measurement Institute, 
Pymble, Australia 
Standard IV 
[14C] UDP glucuronic 
acid 
PerkinElmer Life and Analytical 
Sciences, Boston, MA 
Co-substrate I-III 
UDP-glucuronic acid 
triammonium salt 
Sigma-Aldrich, St. Louis, MO Co-substrate I-VI 
UDP-glucuronic acid 
trisodium salt 
Sigma-Aldrich, St. Louis, MO Co-substrate VI 
Umbelliferone Sigma-Aldrich, St. Louis, MO Substrate I, II 
Umbelliferyl ?-D-
glucuronide 
Sigma-Aldrich, St. Louis, MO Standard I, II 
Water Millipore, Molsheim, France Activity assay, 
HPLC 
I-VI 
ZnSO4 Sigma-Aldrich, St. Louis, MO Activity assay I, II 
 
4.1.2. Microsomes and RNA sources 
 
Enzyme and RNA sources other than in-house expressed UGTs (see 4.4.1.2.) are listed in 
Table 4.  
Table 4. Enzyme and RNA sources used in this study. 
Enzyme/RNA source Supplier Publi-cation 
Gunn rat microsomes Tytgat Institute for Intestinal and Liver Research, 
Academic Medical Center of the University of 
Amsterdam, The Netherlands 
V 
Human adult liver Department of Pharmacology and Experimental 
Therapeutics, Tufts University School of 
Medicine, Boston, MA, USA 
II 
Human adult lung Department of Pharmacology and Experimental 
Therapeutics, Tufts University School of 
Medicine, Boston, MA, USA 
II 
Human adult nasal 
mucosa 
Monell Chemical Senses Center,Philadelphia, PA, 
USA 
II 
Human fetal lung University of Washington Birth Defects Research 
Laboratory, USA 
II 
Human fetal nasal 
mucosa 
University of Washington Birth Defects Research 
Laboratory, USA 
II 
Human lung RNA BD-Clontech, USA II 
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Human Pooled fetal liver 
total RNA 
BD-Clontech, USA II 
Human Pooled small 
intestine mucosa RNA 
Ambion, USA II 
Human UGT2B15 
Supersomes® 
BD Gentest Woburn, MA, USA IV, 
VI 
Pooled human intestinal 
microsomes (HIM) 
BD Gentest Woburn, MA, USA VI 
Pooled human liver 
microsomes (HLM) 
BD Gentest Woburn, MA, USA VI 
 
4.2 PATIENTS 
 
Publications II and V included investigations on Dutch Crigler-Najjar patients. Details of 
the patients, including the type of Crigler-Najjar syndrome, gender, mutations, presence of 
the UGT1A1*28 promoter mutation (7 TA repeats compared to the wild type 6 TA 
repeats), and the treatments of individual patients are listed in Table 5. The information 
about the treatments of the patients is as of 2009 and the information that was published 
first in publication II of this thesis, provided by Dr. Piter Bosma, was obtained under the 
approval of the Ethical committee of the University of Amsterdam.  
Table 5. Crigler-Najjar patient data. OLT: orthotopic liver transplant, PT: phototherapy (hours per 
 day), Phe: patient treated with phenobarbital. 
Patient 
no. 
Gender Mutant proteins *28 Treatment Reference 
Crigler-Najjar Type I  
1 M Q49X/del exon 4 6/6 OLT (Gantla et al., 1998) 
2 F K407X/Y74X 6/6 PT 9 (Zmetakova et al., 2007; 
Kadakol et al., 2000) 
3 F K407X/K407X 6/6 PT 7 (Zmetakova et al., 2007) 
4 M K407X/K407X 6 /6 PT 10 (Zmetakova et al., 2007) 
5 F K407X/K407X 6/6 PT 10 (Zmetakova et al., 2007) 
6 M K407X/K407X 6/6 PT 10-14 (Zmetakova et al., 2007) 
7 F K407X/K407X 6/6 PT 10 (Zmetakova et al., 2007) 
8 F K402T/K402T 6/6 PT 10 II 
9 M L443P/L443P 6/6 ? (D'Apolito et al., 2007) 
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Crigler-Najjar Type II 
10 F L15R/L15R 7/7 PT 2 (Seppen et al., 1996) 
11 M L15R/K407X 7/6 PT 2, Phe (Seppen et al., 1996) 
12 F L15R/S191F 7/7 PT 2 II 
13 M G71R/K407X 6/6 Phe (Zmetakova et al., 2007; 
Aono et al., 1993) 
14  M R209W/R209W 6/6  (Bosma et al., 1993) 
15  F R209W/R209W 6/6  (Bosma et al., 1993) 
16 M R336W/A498X 7/6 PT 12, 
Phe 
(Ciotti et al., 1998, II) 
17  M R336W/A498X 7/6 PT 12, 
Phe 
(Ciotti et al., 1998, 
II) 
18 M L15R/L15R 7/7 Phe (Seppen et al., 1996) 
19 F P387H/wt 6/7 Phe II 
 
4.3. ANIMAL EXPERIMENTS 
 
Publication V included animal experiments that were conducted in the Tytgat Institute for 
Intestinal and Liver Research, Netherlands. The experiments were performed in 
accordance with the animal ethics committee guidelines of the Academic Medical Center 
of Amsterdam. The Gunn rats were 8–10 weeks old, weighing 180-200 g (males) or 120-
150 g (females). The rats received an intra-portal venous injection of scAAV2/8-LP1-
UGT1A1 that provides the hepatic expression of human UGT1A1 (Montenegro-Miranda 
et  al.,  2011).  The  doses  of  scAAV were  either  high  (1  ×  1012 genome copies [GC]/kg), 
medium (3 × 1011 GC/kg), low (1 × 1011 GC/kg), or none (negative control). Rat liver 
microsomes were isolated as previously described (Seppen et al., 2006). 
 
The rats received ezetimibe (2 mg/kg) i.p. Blood samples were collected using heparin 
tubes, before the injection and at different time intervals following it. Heparin tubes were 
centrifuged for 1 min at 10,000 × g to obtain plasma. 
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4.4 METHODS 
4.4.1 Molecular biology 
4.4.1.1 Cloning 
Recombinant human UGTs were either cloned in our lab (Kurkela et al., 2003; Kuuranne 
et al., 2003) or obtained from the collaborating laboratories of Professor Peter Mackenzie 
(UGTs 1A5, 2B10, 2B11, 2B17, and 2B28) or Professor Michael Court (UGT2A3). 
UGT2A1  was  cloned  in  the  laboratory  of  Dr.  Ding  (I).  UGT2A2  was  constructed  by  
amplifying exon 1 of UGT2A2 from genomic DNA and ligating it to exons 2-6 of 
UGT2A1 after some DNA manipulation. UGT2A1 cDNA was provided by Dr. Xinxin 
Ding  and  Dr.  Xiuling  Zhang  from  Wadsworth  Center,  New  York  State  Department  of  
Health.  
 
UGT1A1 and UGT1A10 mutations (II, III) were created using the QuikChange system 
(Stratagene, La Jolla, CA, USA) or by a procedure described by Deng and Nickoloff, 
(1992). The amplified genes were subcloned into pFB-XHA or pFB-XHC vectors 
(Kurkela et al., 2003). The cloned genes were sequenced entirely to confirm the sequence 
and to exclude additional alterations. 
4.4.1.2. UGT expression in Sf9 cells 
All the recombinant UGTs and the mutants, except UGT2B15, were expressed in-house as 
His-tagged proteins. The expression was done in baculovirus infected Sf9 insect cells 
according to the Bac-to-Bac® Baculovirus Expression System (Invitrogen). Briefly, 
recombinant baculoviruses were generated by transposition in the E.coli bacterial strain 
DH10Bac, after which bacmid DNA was isolated. Sf9 cells were transfected with the 
bacmid using the Cellfectin reagent and viruses were harvested from the transfected insect 
cell medium according to the manufacturer's instructions. The optimal infection size was 
determined by infecting parallel cell suspensions of constant cell concentration with 
different amounts of recombinant baculovirus, and by assaying enzyme activity in the 
collected cells 48 h post infection. For protein production, the cells (2x106 cells/ml) were 
cultured in suspension with constant stirring at 27?C in HyClone SFX-Insect medium 
(Thermo Scientific, Waltham, MA) supplemented with 10% heat-inactivated fetal bovine 
serum. The cells were harvested approximately 48 hours after infection. The membranes 
(microsomes) were isolated from the harvested cells as described before (Kurkela et al., 
2003). 
4.4.1.3. UGT quantification and visualisation 
The total protein concentration of the isolated membranes was measured using the 
bicinchonic acid (BCA) assay kit according to the manufacturer's instructions (Pierce, 
Rockford, IL). The relative expression levels of individual UGTs, carrying C-terminal 
His-Tag, were determined using the monoclonal tetra-His antibodies (Qiagen, Hilden, 
Germany). The relative expression levels reflect the ratio of UGT protein versus total 
protein and they were used to normalize the actual rates obtained from UGT activity 
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assays. In publication II, Western-blotting was performed to confirm proper expression of 
all UGT1A1 mutant proteins, i.e. that none of them contained a pre-mature stop codon. 
 
Expression  of  UGT2A1,  UGT2A2,  and  UGT2A3  in  human  tissues  was  screened  using  
RT-PCR and subsequently quantified by quantitative real-time PCR (qRT-PCR). The 
expression  of  UGT2A2  mRNA  was  confirmed  from  fetal  nasal  mucosa  by  PCR  
amplification and sequencing (I). This work was done in a collaborative laboratory at the 
Tufts University, Boston, Massachusetts.  
4.4.2 Glucuronidation assays 
The glucuronidation activity assay samples contained 50 mM phosphate buffer pH 7.4, 10 
mM MgCl2, 0.01-20 mg/mL of enzyme source (total protein), 1-5 mM UDPGA and 1-
4000 µM of aglycone substrate, dissolved in up to 100% dimethyl sulfoxide (DMSO). The 
final DMSO concentration in the assays was max 10% and the total sample volume was 
100 ?l.  This amount of DMSO does not significantly reduce UGT activity (Zhang et  al.,  
2011). When the enzyme source was HLM, HIM, or rat liver microsomes, 5% alamethicin 
was also added to the mixture to activate the latent UGT activity in these microsomes 
(V,VI). 
 
The reactions were initiated by the addition of UDPGA, then carried on for 15-150 min at 
37 °C and terminated by the addition of either 10 ?l ice-cold 4 M perchloric acid, 100 ?l 
methanol (MeOH), or 20 µl of cold ZnSo4 and 200 µl MeOH depending on the substrate 
used. The samples were thereafter transferred to ice for 10 min and the proteins were 
finally sedimented by centrifugation at 16100 g (room temperature). The supernatants 
from these centrifugations were transferred in to vials and analysed immediately. 
4.4.3 Analytical methods and data analysis 
Supernatants were analysed by HPLC, using either a Shimadzu LC-10 model (Shimadzu 
Corporation,  Kyoto,  Japan),  an  Agilent  1100  (Agilent  Technologies,  Palo  Alto,  CA,  
USA), or an ultra-performance liquid chromatography quadrupole time of flight mass 
spectrometry (UPLC-QTOF) (Waters/Micromass, Manchester, UK). The analytical 
methods used for separation of the glucuronides and aglycone substrates were developed 
by the author or described in previous publications from our laboratory. Details of the 
methods are provided in publications I-VI.  
 
Detection of glucuronides was performed in most cases with a fluorescence detector, but if 
the glucuronides did not exhibit fluorescence, an ultraviolet (UV) detector or MS was 
used. In most cases the glucuronides were identified and quantified using authentic 
glucuronides as external standards. If authentic glucuronides were not available, the 
quantification was done with external standard curve generated with the unconjugated 
substrate, as in the case of bilirubin, or by a combination of radioactive and fluorescence 
detection, as for 4-phenylphenol. In the latter case, the reactions contained 50 µmol/l 
unlabelled UDPGA, and 11.1 µmol/l radiolabeled [14C] UDPGA. The samples were 
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analysed with HPLC combined with a radiochemical detector (Model 9701, Reeve 
Analytical, Glasgow, UK). The glucuronides were quantified by the peak areas of the 
[14C] UDPGA-containing metabolites. 
 
In the case of estriol stereoisomers, where three different glucuronides were possible and 
authentic glucuronides were not available for determining the retention time of each 
glucuronide, we used NMR for the identification of distinct estriol glucuronides (VI). 
Large amounts of individual glucuronides were biosynthesised with recombinant 
enzymes, fractionated using an Agilent 1100 HPLC, and the specific fractions were 
collected. The glucuronide fractions were concentrated using a rotary evaporator and 
lyophilized. The lyophilized glucuronides were redissolved in deuterated methanol and 
subjected to NMR spectroscopy on a Varian 300 MHz MercuryPlus spectrometer (Varian, 
Inc., Palo Alto, CA). 
 
The enzyme kinetic constants  were determined by fitting the experimental data using 
GraphPad Prism 4.02 or 5.04 for Windows (GraphPad Software, San Diego, CA, USA) (I, 
III, IV, VI). The data was fitted to either the Michaelis–Menten, Michaelis–Menten with 
substrate inhibition, or biphasic kinetic models. The equations used were as follow: 
 
Michaelis-Menten equation: 
 
1. ? = Vmax × [S]
Km  + [S]
 
 
Michaelis-Menten with substrate inhibition: 
 
2. ? = Vmax  × [S]
Km + [S] × (1+
[S]
Ki
)
 
 
Biphasic kinetics: 
 
3. ? =  Vmax1 × [S] 
Km1+[S]
 + Vmax2 × [S] 
Km2+[S]
 
 
 
? (Initial) reaction rate 
Vmax Maximum enzyme velocity 
[S] Substrate concentration 
Km Michaelis-Menten constant, substrate concentration at ½ Vmax 
Ki Dissociation constant for enzyme-inhibitor complex 
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4.4.4 Molecular modelling 
A homology model for UGT1A10 (III) was constructed using Modeler 9v6 similarly to 
the previous work with UGT1A1 (Laakkonen and Finel, 2010). Briefly, human UGT2B7 
was used as a template for the enzyme C-terminal domain and three templates were used 
for the N-terminal domain: UGT72B1 from Arabidopsis thaliana, GtfB from 
Amycolatopsis orientalis and macrolide glycosyltransferase from Streptomyces 
antibioticus. The substrate structures were built and optimized in MOPAC2009 
(http://openmopac.net) and docked into the active site based on the interactions with 
catalytic histidine (His37) and UDPGA. (III, Laakkonen and Finel, 2010) 
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5. RESULTS AND DISCUSSION 
5.1. UGT1A1 AND CRIGLER-NAJJAR SYNDROME 
5.1.1 UGT1A1 mutations in CN patients in the Netherlands 
The UGT1A1 missense mutant enzymes found in Dutch Crigler-Najjar patients were 
investigated in publication II. In total, 14 different UGT1A1 mutations were found in the 
set of CN-patients, of which 4 were novel (Table 5). Eleven patients had at least one of the 
two mutations frequently detected in the Netherlands, K407X and L15R. Many of them 
are nonrelated, which suggests that both are founder mutations.  
 
Of the identified mutations, the missense mutants G71R, S191F, R209W, R336W, P387H, 
K402T, and L443P identified from patients 8, 9, 12-17 and 19 were studied more closely 
(Table 5, Fig. 10). Two mutations, L15R and Y486D, were not included because both had 
been studied before (Seppen et al., 1996; Kurkela et al., 2007) and also because L15R 
mutation is located in UGT1A signal sequence and probably affects the expression level of 
the protein more than the activity of the produced protein. Nonsense mutations, i.e. point 
mutations such as Q49X that result in a premature stop codon, were also not included 
since they are most likely degraded before or after translation. Instead, three previously 
reported mutations were included for comparison: L175P, Q331R, and G395V (Seppen et 
al., 1994; D'Apolito et al., 2007; Moghrabi et al., 1993). 
 
As seen in Figure 10, mutations G71R, L175Q, S191F, and R209W lie in the putative 
aglycone binding area and may affect the binding of aglycone substrate. L175 may be one 
of the hydrophobic residues forming a hydrophobic pocket for aglycone binding.  
 
Mutations P387H, G395V, and K402T lie in the highly conserved UGT signature 
sequence. This sequence contains the UDPGA binding site and the conserved amino acids 
are thought to be important or even essential for UDPGA binding and enzyme activity 
(Miley et al., 2007). Mutations Q331R and R336W are also located near the UDPGA 
binding site and may affect the affinity of UDPGA to the enzyme. L443P lies further away 
from the UDPGA binding site, in the middle of ?-helix C?7 (Miley et al., 2007). Proline is 
known to disrupt or break ?-helixes because its amine group is bonded to the side chain 
and  thus  cannot  form  a  hydrogen  bond.  Therefore  it  is  possible  that  a  mutation  from  
leucine to proline might end the ?-helix and disrupt the three dimensional structure of the 
enzyme, affecting its catalytic activity. 
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 Schematic representation of UGT1A1 primary sequence and the locations of the missense Figure 10.
 mutations examined. 
It is noteworthy that mutations in exons 2-5, region common to all UGT1A enzymes, are 
present in all nine UGT1A enzymes. That is, patients with mutations Q331R, R336W, 
P387H, G395W, K402T, and L443P are prone to reduced activity in the glucuronidation 
of many other endobiotic and xenobiotic UGT substrates besides bilirubin. For example, 
propofol is an anesthetic that is almost exclusively metabolised by UGT1A9 (Court, 
2005), hence mutations in UGT1 exons 2-5 are likely to affect the metabolism of this drug. 
 
Western-blot analyses were performed to confirm proper expression of all missense 
mutants, revealing an increased Mr for mutant K402T (Fig. 11). Closer examination of the 
sequence  of  this  mutant  revealed  that  this  is  most  likely  due  to  an  additional  N-
glycosylation site generated by the mutation. The mutant sequence 400NATR403 is strongly 
predicted to contain a glycosylation site while the wild type 400NAKR403 sequence is not 
(NetNGlyc 1.0 Server). 
 
 
 
 Western-Blot wild type UGT1A1and UGT1A1K402T. K402T has increased molecular mass due to Figure 11.
 the new N-glycosylation site. (II) 
UGT1A1  UGT1A1K402T 
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5.1.2 Bilirubin glucuronidation activity of ten UGT1A1 missense mutants 
One of the main aims of this study was to evaluate the effect of the missense mutations on 
the bilirubin glucuronidation activity and to examine the correlation of in vitro results with 
the severity of hyperbilirubinemia. The correlation between residual UGT1A1 activity at 
the protein level and patient phenotype has relevance in predicting the severity of the 
syndrome in newly identified patients. For this, bilirubin glucuronidation assays were 
performed, with all the mutant proteins as well as wild type UGT1A1 (Fig. 12). 
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 Bilirubin glucuronidating activity of wild type UGT1A1 and ten UGT1A1 mutants. The results Figure 12.
 are normalised for differences in enzyme expression as determined by dot-blot analysis. (II) 
Mutants G71R, L175Q, S191F, R209W, and R336W showed some residual bilirubin 
glucuronidating activity and they are all indeed found in patients diagnosed with CN-II. 
G71R is a relatively common GS-causing mutation in Asian population. Patient 13 
exhibiting this mutation, however, presents a CN-II phenotype, but this is explained by 
compound heterozygous genotype G71R/Y486D. 
 
Mutants Q331R, P387H, G395V, K402T, and L443P did not show any bilirubin 
glucuronidation activity, but only K402T and L443P were found in patients with CN-I. 
Mutations P387H and G395V were identified in heterozygous CN-II patients and the other 
allele probably had enough residual bilirubin glucuronidating activity which could explain 
the phenotype. Mutation Q331R was identified in a homozygous patient with CN-II. 
Assuming that this patient was indeed homozygous for the Q331R, there is an apparent 
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contradiction in this case between the bilirubin glucuronidation activity in vitro and the 
severity of the disease in vivo. One explanation for this might be that the in vivo activity is 
derived from heterodimer formation that rescues part of the enzymatic activity (Kurkela et 
al., 2007). It might also be possible that this mutation causes folding defects and these 
folding defects are more severe in the insect cell expression system because of the 
different composition of chaperone proteins compared to humans. Further research is 
needed to understand this observation in full. 
 
5.1.3 Activity of UGT1A1 missense mutants toward other substrates  
UGT1A1 has many other substrates besides bilirubin and we also studied the effect of the 
missense mutations on the glucuronidating activity of eight UGT1A1 substrates (Table 6). 
The results show that the effects of the mutations on bilirubin glucuronidation generally 
correlate well with the activity toward other substrates.  
Table 6. Activity of 10 UGT1A1 missense mutants towards tested substrates. The symbols represent 
 the mutant proteins glucuronidation activity compared to wild type UGT1A1. -: no activity 
 detected; (+): 0.1-2.5% activity; +: 2.5-10% activity; ++: 10-25% activity; +++: 25-50% 
 activity and ++++: over 50% activity. 
Substrate G71R L175Q S191F R209W Q331R R336W P387H G395V K402T L443P 
Bilirubin  ++ + + + - (+) - - - - 
17?-estradiol +++ (+) ++ (+) - - - - - - 
17?-ethinyl-
estradiol 
++++ (+) +++ (+) - - - (+) (+) - 
1-hydroxy-
pyrene 
++ - ++ - - - - (+) - - 
4-methyl-
umbelliferone 
++++ (+) +++ (+) - - - (+) - - 
?-naphthol +++ (+) + (+) (+) - - - - - 
4-nitrophenol +++ (+) ++ + (+) - - - - - 
Scopoletin ++++ ++ ++ ++ (+) (+) - (+) - - 
Umbelliferone ++++ (+) ++ + - - - (+) - (+) 
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Some mutant enzymes (Q331R, G395V, K402T, and L443P) exhibited activity for one or 
more  substrates,  although  they  did  not  glucuronidate  bilirubin.  It  is  possible  that  these  
mutations are targeted to an amino acid residue that is specific for bilirubin binding. A 
more likely explanation is, however, that since the sensitivity of the bilirubin method was 
lower than with most other methods, some of these mutant proteins did in fact exhibit 
minor bilirubin glucuronidation activity, but the yield of glucuronides remained below the 
detection limit of the method. 
 
5.1.4 Biomarker for efficacy of gene therapy for Crigler-Najjar syndrome 
As noted in section 2.2.3.2,  the efficacy of gene therapy for CN cannot be monitored by 
serum bilirubin quantification since daily phototherapy of CN-I patients cannot be halted. 
The possibilities to determine the efficacy of scAAV2/8-LP1-UGT1A1 treatment were 
investigated in publication V. One option to estimate the efficacy of gene therapy 
treatment would naturally appear to be the assessment of bile glucuronides. Closer 
inspection, however, revealed that not only does bile analysis require an invasive 
endoscopy, the amount of bilirubin glucuronides in bile correlated poorly with the clinical 
status of CN patients (see publication V for detailed results). This indicates that the 
amount of bilirubin glucuronides in bile cannot be used in evaluating whether or not it is 
safe to cease phototherapy. Therefore we turned to exogenous UGT1A1 substrates in 
search of nontoxic and specific marker that would confirm the activity level of UGT1A1 
and, thereby, the efficacy of the gene therapy treatment. Three compounds were tested for 
this purpose: estradiol, ethinylestradiol and ezetimibe (Fig. 13). These compounds were 
selected based on previous knowledge of their nontoxicity and selectivity for (human) 
UGT1A1. In the case of estradiol, selectivity applies when giving this compound 
intravenously to bypass the high activity of UGT1A10 in the intestine. (Lepine et al., 
2004; Itaaho et al., 2008; Ghosal et al., 2004; Ebner et al., 1993). 
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 Structures of estradiol (A), ethinylestradiol (B), and ezetimibe (C). Figure 13.
The glucuronidation of estradiol, ethinylestradiol, and ezetimibe was first tested in vitro, 
using liver microsomes from Gunn rats that received a single injection of scAAV2/8-LP1-
UGT1A1, encoding human UGT1A1 (Fig. 14). Assays for bilirubin glucuronidation were 
also included to ensure UGT1A1 activity and to monitor the therapeutic effect of the virus 
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dose. The results revealed a good correlation between the different levels of the gene 
therapy treatment and bilirubin glucuronidation rates. The highest bilirubin 
glucuronidation rates were observed with microsomes from rats that were treated with a 
high dose of scAAV, while microsomes from non-treaded control rats showed no bilirubin 
glucuronidation activity. Even with the lowest virus dose the reduction of serum bilirubin 
in rats was in the magnitude that would be therapeutic in CN-I patients (results not 
shown).  
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 Glucuronidation activities measured from Gunn rat liver microsomes. The doses of AAV carrying Figure 14.
 UGT1A1 were high (1×1012 GC/kg), medium (3×1011 GC/kg), or none (Ctrl). Untreated male 
 control Gunn rats showed no activity for bilirubin or ezetimibe glucuronidation. 
Estradiol and ethinylestradiol glucuronidation at the 3-OH proved to be unsuitable for the 
biomarker role, because the glucuronidation activity in control microsomes was in the 
same range as in microsomes from rats that were treated with the medium and high 
amounts of scAAV. This indicates that one or more hepatic rat UGT2B can catalyse these 
reactions at relatively high rates. Ezetimibe appeared more suitable, since its 
glucuronidation rate in untreated control male Gunn rat microsomes was below the 
detection limit and clearly higher in microsomes from treated rats. In female rats, 
however, background ezetimibe glucuronidation activity was observed. One explanation 
for  this  could  be  gender  differences  in  the  expression  of  UGT2Bs  in  rats.  One  or  more  
UGT2B enzyme, which catalyses the glucuronidation of ezetimibe, might be expressed at 
higher levels in female rats compared to male rats and this could explain the increased 
ezetimibe glucuronidation activity observed in liver microsomes from female Gunn rats. 
Gender differences in UGT activity have been reported in rats, for example female Wistar 
rats have been found to conjugate bilirubin at two-fold higher rates compared to males 
(Muraca and Fevery, 1984). In humans, UGT2B15 and UGT2B7 have been also reported 
to glucuronidate ezetimibe, and UGT2B15 is known to be up regulated by estrogen 
(Ghosal et al., 2004; Harrington et al., 2006). We could speculate that a rat equivalent of 
UGT2B15 could be responsible for the increased ezetimibe glucuronidation activity in 
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female  Gunn  rats,  but  since  rat  UGTs  are  not  thoroughly  characterized,  this  remains  a  
hypothesis. 
 
Ezetimibe conjugation was subsequently studied in Gunn rats in vivo in a collaborating 
laboratory. Serum concentrations of ezetimibe and its glucuronide were measured and the 
correlation between ezetimibe glucuronidation and bilirubin reduction was determined. A 
clear correlation between the reduction of unconjugated bilirubin concentration and 
increased ezetimibe glucuronidation was observed in both male and female rats that were 
treated with UGT1A1-carrying scAAV (Fig. 15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Correlation between ezetimibe glucuronidation and the degree of serum bilirubin correction (i.e. Figure 15.
 reduction of bilirubin) 20 min after injection  in rats that were treated with UGT1A1-carrying 
 scAAV. (V) 
The reduction was seen in both sexes in vivo,  and  although the  results  from the  in vitro 
assays demonstrated a large difference between control male and female samples, the in 
vivo assays revealed that there is a clear difference in the ezetimibe glucuronidation rate 
between treated and untreated rats, also in female rats (results not shown).  
 
While these results suggest that ezetimibe is a suitable biomarker for UGT1A1 activity in 
vivo, it should be highlighted that since some UGT1A3 activity in ezetimibe 
glucuronidation has been reported (Ghosal et al., 2004), ezetimibe might be suitable as a 
biomarker mainly for CN patients with a mutation in exons 2–5 and not in exon 1. In 
future clinical studies, the suitability of ezetimibe as a biomarker for gene therapy should 
be evaluated separately for patients who have the inactivating mutation in the first exon. 
Furthermore, although ezetimibe appears to be a good biomarker for UGT1A1 activity in 
rats, the same does not necessarily apply in humans due to interspecies differences in 
glucuronidation and further studies are therefore needed. 
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5.2 EXPRESSION AND CHARACTERISATION OF UGT2A2 
 
The novel UGT2A2 enzyme was characterised in publication I.  The  expression  of  
UGT2A1, UGT2A2, and UGT2A3, relative to 18S rRNA expression, was determined by 
qRT-PCR from human fetal nasal mucosa, adult nasal mucosa, fetal lung, adult lung, fetal 
liver, adult liver, and adult small intestine mucosa (Fig 16). 
 
 
 Expression of UGT2A1, UGT2A2, and UGT2A3 isoform mRNA in human tissues. Results are Figure 16.
 normalized to 18S rRNA content. # represents individual donors and in pooled samples the number 
 of donors is represented in brackets. (I) 
UGT2A2, as well as UGT2A1, mRNA was mainly detected in human fetal and adult nasal 
mucosa. UGT2A2 exon 1 expression was previously reported in duodenum and jejunum 
in a review article with limited experimental details (Tukey and Strassburg, 2001) and we 
too found UGT2A2 in the small intestine, although only in trace amounts. With UGT2A1 
and 2A3, our data was in agreement with the previously reported results (Jedlitschky et al., 
1999; Court et al., 2008; Somers et al., 2007; Thum et al., 2006). According to our results, 
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UGT2A2’s expression pattern is closely similar to the expression pattern of UGT2A1. An 
interesting finding was also that the mRNA levels were significantly higher in fetal nasal 
samples compared to adult ones. The prenatal expression might be an evolutionary relic, 
but it is also possible that these enzymes are involved in glucuronidating compounds 
present in the amniotic fluid around the developing fetus and thus limiting the intake of 
possibly harmful chemicals. For example, several drugs are able to cross the placental wall 
and reach the fetus. If the drug is subsequently excreted renally by the fetus, it enters the 
amniotic fluid and is subject to recirculation via amniotic aspiration, which occurs nasally 
as well as via mouth (Morgan, 1997). There are also indications of prenatal olfactory 
function  in  humans  (Faas  et  al.,  2000;  Schaal  et  al.,  2000;  Schaal  et  al.,  1998),  so  nasal  
UGTs might be responsible for olfactory signal termination also in the fetus. 
 
Keeping in mind the exon sharing between UGT2A1 and UGT2A2 (see section 2.1), 
UGT2A2 cDNA was constructed by first amplifying exon 1 from genomic DNA and then 
ligating it to the exons 2-6 of UGT2A1 that was cloned in a collaborating laboratory. The 
cloned  UGT2A2,  as  well  as  the  cloned  UGT2A1  and  UGT2A3,  were  expressed  in  Sf9  
cells and their activities were tested using various substrates (Table 7). 
Table 7. Glucuronidation rates of UGT2As with selected aglycone substrates. The rates are expressed as 
 mean ±SD (pmol/min/mg) and the concentration of the aglycone substrates was 200 µM. Nd, 
 no glucuronides detected; Det, glucuronides detected below quantification limit. 
Substrate 2A1 2A2 2A3 
4-aminobiphenyl  Nd Nd Nd 
Estradiol (3-glucuronide)   0.70 ± 0.03 1.50 ± 0.03 Nd 
Estradiol (17-glucuronide)   2.2 ± 0.1 Det Nd 
Estriol (3-glucuronide)  Nd Nd Nd 
Estriol (16 or 17-glucuronide)  14.1 ± 0.5 0.10 ± 0.03 Nd 
Ethinylestradiol  Det 9.5 ± 0.5 Nd 
1-hydroxypyrene   198 ± 2 5.3 ± 0.1 Nd 
Hyodeoxycholic acid    2.1 ± 0.1 8.1 ± 0.5 4.9 ± 0.4 
4-methylumbelliferone    548 ± 40 2.9 ± 0.1 Nd 
1-naphthol    314 ± 24 4.1 ± 0.1 Nd 
4-nitrophenol    60.1 ± 4 3.6 ± 0.1 Nd 
2-phenylphenol    15.7 ± 0.6 1.3 ± 0.1 Nd 
3-phenylphenol    339 ± 6 62 ± 1 Nd 
4-phenylphenol    249 ± 22 74 ± 2 Nd 
Scopoletin    283 ± 12 7.7 ± 0.1 Nd 
Umbelliferone    233 ± 10 0.60 ± 0.03 Nd 
 
Generally, our results confirmed the broad substrate specificity of UGT2A1 (Jedlitschky et 
al., 1999) and the narrow selectivity of UGT2A3 (Court et al., 2008). UGT2A1 
glucuronidated all the compounds that were recognized as UGT2A1 substrates before, and 
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in our set of substrates, UGT2A3 exhibited glucuronidating activity only towards the bile 
acid hyodeoxycholic acid was found to have similar substrate specificity as UGT2A1, but 
lower glucuronidation rates. Exceptions to this rule were found with hyodeoxycholic acid 
conjugation, in which UGT2A2 exhibited a higher glucuronidation rate, and in the 
glucuronidation of estrogens, where there were differences in both regiospecificity and in 
glucuronidation rates (discussed in more detail in section 5.3.1). The difference in the 
glucuronidation rate of hyodeoxycholic acid by UGT2A1 and UGT2A2 was recently 
confirmed by another group, which also demonstrated that these enzymes, particularly 
UGT2A2, glucuronidate other bile acids at high rates (Perreault et al., 2013). Why these 
enzymes glucuronidate bile acids is unclear, since they are not expressed extensively in 
tissues that are exposed to them (Court et al., 2012). 
 
To assess whether the generally lower glucuronidation activity of UGT2A2 was due to 
weaker substrate affinity or lower turnover rates, we performed enzyme kinetic assays 
with selected substrates, namely 4-nitrophenol, 4-phenylphenol, 4-methylumbelliferone, 
and the co-substrate UDPGA. With UGT2A1, 4-nitrophenol followed Michaelis–Menten 
kinetics, 4-methylumbelliferone Michaelis–Menten kinetics with substrate inhibition and 
4-phenylphenol biphasic kinetics. With UGT2A2, all substrates followed Michaelis-
Menten kinetics. Kinetic constants are presented in Table 8.  
Table 8. Kinetic constants for the glucuronidation of 4-nitrophenol, 4-methylumbelliferone, and 4-
 phenylphenol by UGT2A1 and UGT2A2 and for a UDPGA with either 500 µM 4-methyl-
 umbelliferone (UGT2A1), or 750 µM 4-phenylphenol (UGT2A2).  Values are represented as 
 mean ± SD from triplicate incubations in µM (Km values) or pmol/min/mg (Vmax values). Ki value 
 (in µM) is presented in the case of Michaelis–Menten kinetics with substrate inhibition. 
 UDPGA 4-nitrophenol 4-methyl-umbelliferone 4-phenylphenol 
 Km  Vmax  Km  Vmax  Km  Vmax  Km  Vmax  
UGT2A1 39.5 ± 
8.9 
292 ± 
12 
303 ± 35 141 ± 5 32.3 ± 2.2 537 ± 
13 
0.9 ± 0.3 (Km1) 116 ± 10 
(Vmax1) 
     Ki, 2135 ± 
240 
 614 ± 221 (Km2) 325 ± 49 
(Vmax2) 
UGT2A2 55.1 ± 
7.7 
91.4 ± 
3 
4469 ± 
295 
69 ± 3 2998 ± 123 39 ± 
0.9 
245.0 ± 12 124 ± 2 
 
UGT2A2 was found to have significantly higher Km values for all the aglycone substrates 
tested while both enzymes have approximately equal affinity to UDPGA. The Km values 
for UDPGA were slightly lower compared to previous studies with other UGTs (see,  for 
example, Patana et al., 2007; Luukkanen et al., 2005). This might be a trait specific for 
UGT2A1 and UGT2A2, or arise from the aglycone compound used. The Vmax values for 
UGT2A2 were also generally lower compared to UGT2A1, but the differences were not as 
striking  as  with  the  Km values.  It  is,  however,  worth  noting  that  since  the  affinity  of  
UGT2A2 to aglycone substrates is rather poor, the substrate concentrations needed to 
nearly reach these Vmax values would be almost impossible to achieve in a physiological 
environment. 
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The very clear biphasic kinetics of UGT2A1 in 4-phenylphenol glucuronidation, 
confirmed by computer analyses, was an interesting finding. The enzyme seems to have 
two binding sites for this substrate, a low-affinity site and a high affinity one. The high 
affinity binding site possessed a Km value that is exceptionally low for UGTs, which are 
generally considered to be ´low affinity, high capacity´ enzymes. If UGT2A1 forms 
dimers, it may be argued that the dimerisation plays a role in the biphasic kinetics. In our 
studies we used recombinant UGT2A1, meaning that homodimers could form, but not 
heterodimers with other UGTs. It is thus likely that both binding sites lay in UGT2A1, 
either in one or more subunits. In any case, additional studies are needed to identify the 
specific binding sites of the substrates.  
 
In summary, we expressed, and characterized the novel UGT2A2, which was found to be 
a functional enzyme that is expressed in the nasal mucosa. Exon sharing between 
UGT2A1  and  UGT2A2  was  also  confirmed  and  the  substrate  specificities  of  these  
enzymes were found to be closely similar, but not identical. 
5.3 GLUCURONIDATION OF  STEROIDS 
5.3.1. Glucuronidation of estradiol, ethinylestradiol, and estriol by UGT2A1 and 
UGT2A2 
Several differences in the regioselectivity of estradiol, ethinylestradiol, and estriol (see 
Figures 8 and 13 for molecular structures) glucuronidation were found with UGT2A1 and 
UGT2A2. The identification of the conjugation site was, however, limited in the case of 
estriol, since the HPLC method for estriol glucuronidation had a limited resolution and the 
16- and 17-glucuronides could not be distinguished from each other in this study. 
 
UGT2A1 exhibited a clear preference for the 17-OH (or 16-OH in the case of estriol) of 
the tested estrogens (Table 7) and with ethinylestradiol, that has a bulky ethinyl group 
attached to C17, hindering the conjugation at the 17-OH, UGT2A1 was practically 
inactive. On the other hand, for UGT2A2, ethinylestradiol was one of the best substrates 
among these three steroids while UGT2A2 was nearly inactive in estriol glucuronidation. 
5.3.2.  Estrogen glucuronidation and UGT1A10 substrate binding site 
Amino acids F90 and F93 of UGT1A10 were previously suggested to be important in 
estrogen glucuronidation (Starlard-Davenport et al., 2007) and in publication III we 
created several mutations in these residues of UGT1A10 to further study the effect of 
these amino acids on estrogen conjugation. 
 
The activity of the mutants was screened using single concentrations (indicated in 
brackets) of estradiol (100 ?M), estriol (500 ?M), and ethinylestradiol (100 ?M). Results 
with other substrates and kinetic assays are not discussed here. The results with the three 
estrogens are presented in Figure 17. 
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 Glucuronidation of estradiol (A), estriol (B) and ethinylestradiol (C) with UGT1A10 and its 12 Figure 17.
 mutants. Only the formation of 3-glucuronide is presented. 
The results suggest that wild type UGT1A10 is able to glucuronidate estradiol at a 
relatively high rate, but as the D-ring substituents increase in size, the glucuronidation 
rates are reduced (estriol) or even abolished (ethinylestradiol). Interestingly, mutating 
phenylalanine 93 to an amino acid with a smaller side chain, like alanine or glycine, 
cancels out this phenomenon. Therefore we suggest that  the D ring substituents of these 
estrogens clash with F93 at the UGT1A10 active site, creating steric hindrance and 
inhibiting glucuronidation. A UGT1A10 homology model was created based on recent 
work in our group (Laakkonen and Finel, 2010) and it shows both F90 and F93 located in 
a  surface  helix  at  the  far  end  of  the  substrate  binding  site,  but  within  reach  of  large  
substrates like estrogens (Fig. 18). 
 
 
 
 
 
 
 
 
 
 
 Active site of UGT1A10 with the N-terminal domain (in white) up, and the C-terminal domain (in Figure 18.
 dark gray) down. Phenylalanines 90 and 93 catalytic histidine H37 are shown. Estradiol (white), 4-
 nitrophenol (gray) and UDPGA (dark gray) are docked to the active site. (III) 
In summary, the results suggest that F93 of the human UGT1A10 is involved in the 
interactions of the enzyme with ring D of estrogens, but the interactions with smaller 
molecules were found to be less drastic. Most of the F90 mutants were also inactive in 
estrogen glucuronidation, suggesting that this residue is also involved in estrogen binding. 
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5.3.3. Glucuronidation of estriol and estradiol stereoisomers and enantiomeric 
steroids 
The differences found between UGT2A1 and UGT2A2 regioselectivity towards estrogens 
(I) prompted further study of the glucuronidation of steroids and the differences in the 
stereo- and regiospecificity between different UGT enzymes. In publication VI a more 
refined HPLC method was developed for the separation of estriol 16- and 17-glucuronides 
in addition to methods to study 16- and 17-epiestriol and 13-epiestradiol. The 
glucuronidation of enantiomeric steroids was also of interest, thus this was studied in 
publication IV. 
 
The glucuronidation of estriol, 16-epiestriol and 17-epiestriol was first screened by single 
point assays with all the human UGTs (Fig 19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Glucuronidation rates of the estriol (A), 16-epiestriol (B), and 17-epiestriol (C) at 200 µM substrate Figure 19.
 concentration. The glucuronidation rates are corrected according to their relative expression level, 
 except for UGT2B15 (indicated with *). Logarithmic scale is used to make low rates visible. (VI) 
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UGTs 1A10 and 2B7 were the most active enzymes with all the substrates. UGT1A10 was 
the most active UGT in 3-OH glucuronidation, while UGT2B7 was the most active in the 
glucuronidation of D-ring hydroxyls. Regio- and stereochemical differences in the 
glucuronidation patterns were found especially among UGTs 2B4, 2B7, and 2B17. 
UGT2B17 appeared to glucuronidate D-ring hydroxyls exclusively when they were in the 
?-configuration. With UGTs 2B4 and 2B7, the configuration of C17 seemed to dominate 
the glucuronidation pattern: the two enzymes glucuronidated 16-OH when C17 was in ?-
configuration and 17-OH when C17 was in ?-configuration.  
 
Enzyme kinetic assays were performed with the most active UGT enzymes, UGTs 1A10 
and 2B7, as well as with HIM and HLM (results not shown). We had previously noted a 
stimulation of estrogen glucuronidation in the UGT1A10 mutant F93G (see chapter 5.3.2. 
and III) and thus enzyme kinetic assays were performed with this mutant too, to examine 
the effect of the mutation on the conjugation of 16- and 17-epiestriol. Enzyme kinetic 
parameters are presented in Table 9. 
Table 9. Kinetic constants of estriol, 16-epiestriol and 17-epiestriol glucuronidation by UGT1A10, 
 UGT2B7 and UGT1A10 mutant F93G. All assays except those with UGT1A10 and UGT2B7 
 with 16-epiestriol followed Michaelis-Menten kinetics. With UGT1A10 and UGT2B7 and 16-
 epiestriol curves fit best to the Michaelis-Menten with substrate inhibition model. 
  UGT1A10 1A10F93G UGT2B7 
Estriol \ glucuronide formed (3-g) (3-g) (16-g) 
Vmax (pmol/min/mg) 1200 ± 28.1 7535 ± 618 1509 ± 27.7 
Km (µM) 68.4 ± 4.7 230 ± 29.7 10.3 ± 0.8 
        
16-epiestriol \ glucuronide formed (3-g) (3-g) (16-g) 
Vmax (pmol/min/mg) 7700 ± 740 2249 ± 201 3866 ± 788 
Km (µM) 59.8 ± 8.0 186 ± 28.0 38.4 ± 11.4 
Ki (µM) 98.1 ± 16.6   162 ± 86.4 
     
17-epiestriol \ glucuronide formed (3-g) (3-g) (17-g) 
Vmax (pmol/min/mg) 958 ± 75.0 5712 ± 216 820 ± 18.3 
Km (µM) 337 ± 42.1 51.1 ± 5.4 0.6 ± 0.1 
 
 
Kinetic assays revealed that in most cases UGT1A10 and UGT2B7 exhibited relatively 
low affinity and high turnover rates for the different estriols. The exception was UGT2B7 
which had exceptionally low Km value, 0.6 µM, for 17-epiestriol glucuronidation. We had 
previously noted a high affinity of UGT2B7 to epiestradiol (epiestradiol also has the C17 
in ?-configuration; Itaaho et al., 2008) and these results support our current findings. 
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The effect of the F93G mutation on enzyme kinetics was also interesting, when compared 
to  wild  type  UGT1A10.  When  estriol  or  16-epiestriol  was  the  substrate,  the  mutant  
exhibited approximately threefold higher Km value. With 17-epiestriol, the situation was 
opposite and the mutant exhibited higher Vmax value and lower Km value in comparison 
with the wild type UGT1A10. 
 
Since it seemed obvious that the configuration of carbons 16 and 17 at the D ring affects 
the glucuronidation of estrogens, we wanted to see whether the spatial relations between 
the 17-OH and the C13 methyl group also affected the results. 13-epistradiol was the only 
currently available estrogen with C13 in the ?-configuration so this substrate was used to 
screen UGT activity and compare the results with those gained with natural estradiol (Fig. 
20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Glucuronidation rates and structures of the estradiol (A) and 13-epiestradiol (B) at 200 µM Figure 20.
 substrate concentration. The glucuronidation rates are corrected according to their relative 
 expression level, except for UGT2B15 (indicated with *). Logarithmic scale is used to make low 
 rates visible. (VI) 
The results indicated that configurational change at C13 lowered the 3-OH 
glucuronidation activity of most UGT1As, including the F93G mutant of UGT1A10. On 
the other hand, with some enzymes that did not glucuronidate estradiol at the 3-OH, like 
UGT1A9 and 2B17, 3-glucuronides were detectable when 13-epiestradiol was the 
substrate. Conjugation at the 17-OH seemed to be stimulated in many cases, possibly due 
to less steric hindrance at the D-ring. As with 3-OH glucuronidation, some enzymes, 
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namely UGT2A2, UGT2B4 and UGT2B15, showed newly gained activity at the 17-OH 
when 13-epiestradiol was the substrate. 
 
In publication IV, we studied the glucuronidation of the enantiomeric estradiol, 
androsterone, and etiocholanolone. 
 
Like with estriols, the glucuronidation rates were first screened at single substrate 
concentration, 200 µM for ent-estradiol  and  50  µM  for  ent-androsterone and ent-
etiocholanolone (Fig. 21). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Glucuronidation rates of the ent-estradiol (A), ent-androsterone, and ent-etiocholanolone (B).The Figure 21.
 glucuronidation rates are corrected according to their relative expression level, except for 
 UGT2B15 (indicated with *).  
For ent-estradiol, the results resembled the glucuronidation pattern of natural estradiol. 
UGT1As that were active for this substrate conjugated it at the 3-OH. The exception was 
UGT1A4 which conjugated ent-estradiol at the 17-OH. With natural estradiol, UGT1A4 is 
also selective for this hydroxyl. With natural estradiol and epiestradiol (17?-estradiol), 
UGT2A1 and UGT2A2 glucuronidate both hydroxyls, but with ent-estradiol, these 
enzymes were selective only for 17-OH. 
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For UGT2Bs, the results with ent-estradiol, resembled in many cases the glucuronidation 
pattern of natural estradiol; 2Bs, with the exception of UGT2B15, conjugate it at the 17-
OH. Results with UGT2B17 supported our previous finding that this enzyme appears to 
glucuronidate the D-ring hydroxyls exclusively when they are in the ?-configuration. 
UGT2B17 is active toward the natural estradiol but nearly inactive in epiestradiol (Itaaho 
et al., 2008) and ent-17?-estradiol glucuronidation. In this case, the ent-estradiol 
glucuronidation resembles the glucuronidation of epiestradiol rather than natural estradiol. 
 
Enzyme kinetic analyses were subsequently performed for UGTs 1A10, 2A1, and 2B7, the 
most active enzymes in ent-estradiol glucuronidation (results not shown). UGT1A10 was 
confirmed to be the most active enzyme in ent-estradiol glucuronidation, and also to have 
the lowest Km value for the substrate.  
 
Ent-androsterone and ent-etiocholanolone have a single glucuronidation site (3-OH) that is 
in  the  ?-configuration.  It  is  noteworthy  that  this  3-OH  is  different  from  the  3  OH-in  
estrogens, since in estrogens the A-ring is aromatic, making the 3-OH a phenolic 
hydroxyl, while in the androgens the A ring is not aromatic and the 3-OH can be in either 
? or ? configuration. Most UGTs of subfamily 1A that have good activity toward the 3-
OH of ent-estradiol (like UGT1A10), do not glucuronidate ent-androsterone and ent-
etiocholanolone at the 3-OH. Instead, the glucuronidation of these hydroxyls resembles 
the 17-OH glucuronidation of different estrogens. Therefore, we suggest that 
androsterone, etiocholanolone, ent-androsterone, and ent-etiocholanolone are bound to 
UGT1A10 and several other UGT1As active sites in the opposite orientation to that of 
estrogens when they are bound to the same site, so that the 3-OH of these androgens 
occupy the position that, with bound estrogens, is occupied by the 17-OH (Fig. 22). This 
assumption is however purely hypothetical since the structure of UGT active site is 
unknown. 
 
 
 
 
 
 
 
 
 
 Schematic representation of the orientation of ent-estradiol (A) and ent-etiocholanolone (B) in Figure 22.
 UGT active site. 
In summary, with ent-estradiol the UGTs of subfamily 1A and 2A exhibit a higher degree 
of regioselectivity than enantioselectivity but with UGT2Bs, the glucuronidation 
resembles more epiestradiol glucuronidation than estradiol glucuronidation. The 
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glucuronidation of ent-etiocholanolone and ent-androsterone was catalysed mainly by 
UGT2A and 2B enzymes and it resembled the glucuronidation of steroid C17 hydroxyls. 
 
The results of publications IV and VI are summarised in Table 10. The intensity of the 
blue colour indicates the probability of a given UGT to glucuronidate a hydroxyl in a 
certain carbon position and configuration. The intensity of the colour is drawn according 
to the percentage of substrates glucuronidated. For example, UGT1A10 glucuronidated 
phenolic C3 hydroxyls in 6/6 situations. 
Table 10. Heat map presentation of steroid glucuronidation  by different UGTs. Intensity of blue colour 
 correlates positively with the probability of a given UGT to glucuronidate a hydroxyl at 
 certain position and stereochemical configuration. White colour: no activity. 
A-ring D-ring 
  Carbon number C3 
 
C16 
 
C17 
 Configuration  - ? ? ? ? ? 
Steroids i ii iii iv v vi 
1A1   
     1A3     
 
  
 
  
1A4 
 
          
1A5 
      1A6 
      1A7   
     1A8   
     1A9   
     1A10   
    
  
2A1             
2A2     
  
  
 2A3 
      2B4 
 
        
 2B7 
 
          
2B10 
      2B11 
      2B15   
     2B17     
 
  
 
  
2B28 
       
i) Estradiol, ent-estradiol, estriol, 16-epiestriol, 17-epiestriol, 13-epiestradiol 
ii) Ent-androsterone, ent-etiocholanolone 
iii) Estriol, 17-epiestriol 
iv) 16-epiestriol 
v) Ent-estradiol, 17-epiestriol 
vi) Estradiol, estriol, 16-epiestriol 
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The preference of UGT1As (with the exception of UGTs 1A3 and 1A4) and UGT2B15 to 
phenolic C3 hydroxyls is clearly visible. The UGTs 1A3 and 1A4 seem more flexible with 
their  regio-  and  stereoselectivity,  although  UGT1A3  seems  to  be  active  towards  D-ring  
hydroxyls when they are in the ?-configuration and UGT1A4 seems to be completely 
unable to glucuronidate phenolic C3 hydroxyls. The broad substrate specificity of UGTs 
2A1 and 2A2 is also obvious and, especially, UGT2A1 seems to be very flexible for the 
hydroxyl group orientation. UGTs 2B4 and 2B7 seem to prefer D-ring hydroxyls, except 
for C17 in the ?-configuration, and C3 hydroxyls in the ?-configuration. As noted before, 
UGT2B17 seems to be able to glucuronidate D–ring hydroxyls only in the ?-
configuration. 
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6. SUMMARY AND CONCLUSIONS 
This thesis mainly explored three topics: UGT1A1 and familial hyperbilirubinemias (II, 
V), the glucuronidation of different endogenous and synthetic steroids (I, III, IV, VI), as 
well as characterisation of a novel UGT, UGT2A2 (I). 
 
Fourteen different UGT1A1 mutations were identified in 19 CN patients, four of which 
were novel. The results not only broadened the mutational spectrum of CN-syndromes, 
but also hinted at a founder effect of the disease in the Netherlands, which may be useful 
information for the genetic counseling of Dutch CN patients. In vitro studies were 
performed  for  the  first  time  with  seven  of  these  missense  mutants  as  well  as  three  
mutations that were reported previously. Residual UGT1A1 activity and the severity of 
hyperbilirubinemia were found to correlate relatively well with each other in most cases. 
The information gained should help in predicting the severity of the syndrome in newly 
identified patients, especially those who are compound heterozygotes. Additionally, one 
(small) step forward in developing gene therapy for CN-I was obtained in finding that 
ezetimibe glucuronidation correlates with reduction of serum bilirubin in gene therapy 
treated Gunn rats. Ezetimibe thus appears to be a useful biomarker for UGT1A1 activity in 
vivo,  and,  using  it,  the  problem  of  estimating  the  efficacy  of  gene  therapy  treatment  in  
patients receiving phototherapy could be overcome. 
 
This PhD project also involved the expression and characterization of a novel UGT 
enzyme, UGT2A2, and additional studies with UGT2A1 and UGT2A3. UGT2A2 was 
found to be a functional enzyme with broad substrate specificity. The previously 
suggested exon sharing between UGT2A1 and UGT2A2 was confirmed and UGT2A2 was 
found to be expressed mainly in the nasal mucosa. Although otherwise very similar, 
UGT2A1 and UGT2A2 were also found to have large differences in their regiosselectivity 
towards estrogens and this encouraged us to further investigate the conjugation of steroids 
and the differences in the stereo- and regiospecificity in the glucuronidation between 
different human UGTs. 
 
The glucuronidation of estriol, 16-epiestriol, 17-epiestriol, 13-epiestradiol, ent-estradiol, 
ent-androsterone, and ent-etiocholanolone by different UGT enzymes was studied, most of 
them for the first time, and analytical methods for analysing these compounds were 
developed. UGTs 1A10 and 2B7 were found to be the most active UGT enzymes in the 
glucuronidation of almost every steroid studied. While UGT1A10 is mainly expressed in 
the intestine, the most important UGT in in vivo glucuronidation of steroids is probably 
the hepatic UGT2B7. Other UGTs, particularly UGT2A1, also exhibited high turnover 
rates in some cases. Several patterns in the regio- and stereoselectivity of steroid 
conjugation were observed for the first time, like the activity of UGT2B17 toward D –ring 
hydroxyls only in the ?-configuration.  
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The findings with steroid glucuronidation are expected to assist in predicting the 
glucuronidation of drugs that resemble estrogens, as some future anti-cancer drugs are 
expected to. The results may also be useful in the future when the interplay of steroid 
glucuronidation and cancer, like the connection of risk of certain cancers and UGT 
polymorphisms, becomes clearer. The results on steroid glucuronidation are also useful in 
exploring  the  three  dimensional  structure  of  the  UGT  active  site  and  a  model  of  the  
UGT1A10 binding site was constructed based on information gained from estrogen 
glucuronidation studies of UGT1A10 mutants. 
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